GASTROINTESTINAL DEFENSINS, CDNA SEQUENCES AND METHOD FOR THE PRODUCTION AND USE THEREOF

Abstract: This invention provides gastrointestinal peptides useful as antimicrobial and anti-inflammatory agents. This invention also provides methods for producing peptides, pharmaceutical compositions containing the gastrointestinal defensin peptides, and methods of use thereof. Methods of diagnosing gastrointestinal disorders are also provided.

Description: GASTROINTESTINAL DEFENSINS, CDNA SEQUENCES -AND METHOD FOR THE PRODUCTION AND USE THEREOF Field of the Invention The present invention relates generally to defensin peptides referred to herein as gastrointestinal defensin peptides. More particularly, the present invention is related to new members of a class of polypeptide with antimicrobial and anti-inflammatory activity, cDNA and genomic sequences encoding for the peptides, methods for the production and use thereof. Background of the Invention Multicellular organisms utilize a variety of mechanisms to defend against microbial invasion. These include anatomical and chemical barriers, as well as numerous cell- mediated and humoral responses. Collectively these defenses aim to eliminate offending microorganisms. Epithelial surfaces of many tissues are continually exposed to potential pathogenic organisms, yet the incidence of infectious disease following these encounters is relatively small, highlighting the effectiveness of defense mechanisms at these sights. Manifestations of abnormality of these defenses in the intestinal tract may include various forms of diarrhea associated with pathogenic bacteria and ulcerative diseases including inflammatory bowel disease, necrotizing enterocolitis and gastric ulcer disease. Peptide based antimicrobial defense is a conserved component of host defense, and is found in both the animal and plant kingdoms (for reviews see Boman and Hultmark, Ann Rev. Microbiol . , ___1 : 103-126 (1987); Bevins and Zasloff, Ann Rev . Biochem , J59 . : 395-414 (1990) ; Spitznagel, J Clin . Invest . 86: 1381-86 (1990); Bo an, Cell 5: 205-207 (1991); Lehrer et al. , Cell ______: 229-230 (1991)). The size and structure of the antimicrobial peptides shows significant diversity, but in general, they are membrane-active amphipathic molecules with a net positive charge at neutral pH. There are two broadly defined families of these cationic peptides: linear peptides (for example cecropins; Steiner, et al., Nature 292: 246-248 (1981); and againins; (Zasloff, Proc. Natl . Acad . Sci . USA j34.: 5449-5453 (1987)) and cysteine-rich peptides. The latter include mammalian defensins (Ganz et al., Eur J Haematol 4_4: 1- 8 (1990)), tracheal antimicrobial peptide (Diamond, et al., Proc Natl Acad Sci (USA) 88:3952-3956 (1991), bovine bactenecins, (Romeo et al. J Biol Chem 263: 9573-9575 (1988)), insect royalisin, (Fujiwara et al., J Biol Chem 265:11333-11337 (1990)), tachyplesins (Naka ura, et al., J Biol Chem 263: 16709-16713 (1988); Shigenaga, et al., J. Biol Chem 265: 21350- 21354 (1990) , and plant thionins (Olson and Samuelsson, Acta Chem Scand 2_β : 585-595 (1972); Ozaki, et al. ,-J. Biochem 87: 549-555 (1980) ; Bohl ann and Apel, Mol Gen Genetics 207: 446- 454 (1987); Bohlmann, et al., EMBO J 7: 1559-1565 (1988). Defensins are cysteine-rich basic peptides which have been isolated from myeloid-derived cells of several mammalian species (For recent reviews see Ganz, et al., Eur J Haematol 44.:1-8 (1990); Lehrer, et al., Cell SA_: 229-230 (1991). Defensins have in vitro antimicrobial activity against bacteria; Selsted, et al.. Infect Immun 4_5: 150 (1984); Ganz, et al., J Clin Invest !___ _'. 1427-1435 (1985); fungi; Ganz, et al., J Clin Invest 7_6: 1427-1435 (1985); Borenstein, et al., Infect Immun 59_: 1359-67 (1991) ; and enveloped viruses (Lehrer et al., J Virol 54.: 467 (1985); Daher, et al., J Virol 60: 1068-1074 (1986) . Defensins are characterized by eleven conserved residues within the sequence, including six cysteines which participate in intramolecular disulfide bonds (Selsted and Harwig, J Biol Chem 264 . : 4003-4007 (1989). This disulfide array is important for structure and activity of defensins. Evidence suggests that their antimicrobial activity is a direct result of their ability to selectively disrupt membranes (Lehrer, et al., J Clin Invest 84.: 553-561 (1989)); Lichtenstein, J Clin Invest 8.8: 93-100 (1991) , possibly by channel formation (Kagan, et al, Proc Natl Acad Sci (USA) 87: 210-214 (1990)). The high-resolution crystal structure of human defensin-3 has recently been determined (Hill, et al. Science 251: 1481-1485 (1991) , and suggests several specific models for the interaction of defensins with lipid membranes, the site of defensin antimicrobial activity. In addition to antimicrobial activity, certain defensins have other biological activities including, monocyte chemotaxis (Territo, et al., J Clin Invest 84 . : 2017-2020 (1989) , adrenocortical suppression (Singh et al., Bioch Biophys Res Commun 155: 524-529 (1988), nifedipine-sensitive calcium channel activation (MacLeod et al., Proc Natl Acad Sci B8_: 552-556 (1991) and eucaryotic cell cytotoxicity (Okrent et al., Am Rev Respir Dis 141: 179-185 (1990) . In addition to myeloid expression, recent investigations in the mouse (Ouellette and Cordell, Gastroenterol 9 _.' 114-121 (1988), Ouellette et al., J Cell Biol 108: 1687-1695 (1989), Ouellette and Lualdi, J Biol Chem 265: 9831-9837 (1990) and in the cow (Diamond and Bevins, (In preparation) (1991)), Diamond et al., Proc Natl Acad Sci (USA) 88: 3952-3956 (1991) show that the defensin-related peptides, cryptdin and tracheal antimicrobial peptide, are also expressed in epithelial tissues. In humans, defensins are major constituents of the azurophilic granules of neutrophils (Ganz, et al., J Clin Invest 7_6: 1427-1435 (1985) , Selsted, J Clin Invest 7_6: 1436- 1439 (1985) ; Rice, Blood 70: 757-765 (1987) , Lehrer, Hematol Oncol Clin North Am 2 : 159-169 (1988) and are though to contribute to the non-oxidative killing of microorganisms by these circulating leukocytes. (Lehrer et al., Hematol Oncol Clin North Am 2 : 159-169 (1988) . Defensins and other proteins of the azurophilic granules have been shown to enter the phagolysosome vesicles of neutrophils during phagocytosis of bacteria (Joiner et al., J Cell Biol JL0£: 2771-2782 (1989). Four myeloid-derived human defensins have been isolated and characterized (Ganz et al., J Clin Invest 7_6: 1427-1435 (1985); Selsted, et al., J Clin Invest 7_6: 1436-1439 (1985); Singh et al, Bioch Biophys Res Commun 155: 524-529 (1988) , Gabay et al., J Immunol 143: 1358-1365 (1989), Wilde, J Biol Chem 264: 11200- 11203 (1989) . Human defensins 1 and 3 are 30 amino acid peptides, differing in sequence by only a single residue at their amino terminus. (Selsted, et al., J Clin Invest 7_6: 1436- 1439 (1985) . The cloned cDNAs for these two defensins (Daher, et al., Proc Natl Acad Sci USA 85: 7327-7331 (1988); Mars et al., Blood 7_1: 1713-1719 (1988); Wiedemann et al. , Leukemia _3_: 221 -23 (1989) are greater than 98% identical in nucleotide sequence, with a single nucleotide difference in codon 65 of the putative prepropeptides accounting for the alanine or aspartic acid residues in the mature defensins 1 and 3 respectively. Defensin 2, a 29 amino acid peptide, is identical to defensins 1 and 3 except that it lacks either of these amino acids at its amino-terminus (Selsted, et al., J Clin Invest 1_6 : 1436-1439 (1985) . The cDNA for this defensin has not yet been cloned, and it is not clear if it is a product of a distinct gene, or a post-translational proteolytic modification of defensins 1 or 3. Defensin 4 is quite different from other human defensins in primary structure. This 33 residue peptide essentially shares only the consensus residues that characterize defensins (Singh et al., Bioch Biophys Res Commun 155: 524-529 (1988); Wilde, et al., J Biol Chem 264; 11200-11203 (1989) , and neither its cDNA or gene have been described. By in situ hybridization histochemistry, defensin cDNA probes detect a message expressed in a relatively narrow window of granulocyte development. The m NA is abundant in late promyelocytes and early myelocytes, precursors of the mature circulating neutrophils (Mars et al., Leukemia 1 : 167- 172 (1987), Wiedemann, et al., Leukemia 3_: 227-234 (1989), as well as other granular leukocytes (Mars, et al. Leukemia 1 : 167-172 (1987) of human bone marrow, but is undetectable by northern blot analysis in circulating neutrophils (Daher, et al., Proc Natl Acad Sci USA £5: 7327-7331 (1988) . Novel defensin peptides having antimicrobial and anti- inflammatory activity are greatly desired. Defensin peptides particularly suitable for use in the gastrointestinal tract of humans are particularly desireable since they may be effective for treatment of gastrointestinal conditions such as various forms of diarrhea associated with pathogenic bacteria and ulcerative diseases including inflammatory bowel syndrome, necrotizing enterocolitis and gastric ulcer disease. Summary of the Invention The prima- sequence of endogenous host defense peptides reflects evolutionary selection for chemical properties necessary for high activity of peptides in a specific local environment. Defensin peptides endogenous to the human gastrointestinal tract are believed to be suitable for pharmacological use in this organ system and are particularly desirable since they may be effective for treatment of gastrointestinal conditions such as bacterial diarrhea, gastric ulcer disease related to Helicobacter pylori , inflammatory bowel disease, and necrotizing enterocolitis. Furthermore the nucleotide sequence of cDNAs and genes encoding endogenous defensin peptides contain important information for regulated expression. This information can be exploited pharmacologically to alter endogenous expression. These nucleotide sequences can be used diagnostically to detect mutations in these genes and to assess biopsy materials. Thus, the present invention provides novel defensin peptides endogenously localized in the gastrointestinal tract which may be useful for treatment of microbial infection and gastrointestinal inflammation. In accordance with some embodiments of the present invention, substantially pure gastrointestinal defensin peptides are provided comprising at least a portion of an amino acid sequence as defined in SEQ ID NO:5 or SEQ ID NO:7. In other embodiments of the present invention gastrointestinal defensin peptides which are produced from cDNA sequences comprising at least a portion of the sequence defined in SEQ ID NO:4 or SEQ ID NO:6 are provided. Recombinant expression vectors are provided which are capable of expression in a suitable expression system comprising a DNA sequence encoding a gastrointestinal defensin peptide linked to control sequences compatible with the selected expression system. Gastrointestinal defensin peptides produced from such vectors are also provided by the present invention. Contact disinfectants are provided in some embodiments of the present invention comprising an effective amount of a gastrointestinal defensin peptide. In still other embodiments of the present invention pharmaceutical compositions are provided comprising gastrointestinal defensin peptides in a pharmaceutically acceptable carrier. Methods of treating microbial infection and gastrointestinal inflammation are provided in other embodiments of the present invention whereby an antimicrobially effective amount of a gastrointestinal defensin peptide is administered to mammals suffering from a microbial infection or gastrointestinal inflammation. Also provided by the present invention are methods of diagnosing microbial infection of the gastrointestinal tract whereby a sample is taken from a patient and the amount of defensin peptide or mRNA coding for the defensin peptide present in the sample is detected. The amount of gastrointestinal defensin peptide or mRNA in the sample is compared to the amount peptide or mRNA present in a normal mammalian gastrointestinal tract whereby greater or lesser quantities of gastrointestinal defensin peptide or mRNA is indicative of the likelihood of infection. Similarly methods of diagnosing gastrointestinal inflammation are provided whereby a sample is taken from a patient and the amount of defensin peptide or mRNA coding for the defensin peptide present in the sample is detected. The amount of gastrointestinal defensin peptide or mRNA in the sample is compared to the amount peptide or mRNA present in a normal mammalian gastrointestinal tract whereby greater or lesser quantities of gastrointestinal defensin peptide or mRNA is indicative of the likelihood of inflammation. In accordance with other methods of the present invention, the susceptibility of a patient to gastrointestinal disorders may be diagnosed by providing a DNA containing test sample from a human patient and amplifying the DNA from the DNA-cc Gaining test sample using an upstream probe having a sequence complementary to an upstream portion of a defensin sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 4 and SEQ ID NO: 5 and a downstream probe having a sequence complementary to a downstream portion of the selected defensin sequence. The amplified DNA and DNA from a normal sample may be compared to identify mutation f the amplified DNA as compared to normal DNA whereby mutation is indicative of the likelihood that the patient has increased susceptibility to gastrointestinal disorders. A method of identifying a defensin is also provided whereby a library of genomic clones is screened using an oligonucleotide probe derived from evolutionarily conserved defensin sequences. Hybridization of the probe to a clone indicates the likelihood that the clone contains a DNA sequence coding for a defensin peptide. The clone is characterized in some embodiments of the present invention to determine the DNA sequence of the defensin peptide. It is therefore an object of the present invention to provide substantially pure gastrointestinal defensin peptides. It is another object of the invention to provide pharmaceutical compositions useful for the treatment of gastrointestinal microbial infection and inflammation. It is still a further object of the present invention to provide methods of treating and preventing gastrointestinal microbial infections. It is yet a further object of the present invention to provide methods of treating and preventing gastrointestinal inflammation. Methods of diagnosing gastrointestinal microbial infections and gastrointestinal inflammation are also objects of the present invention. Methods of diagnosing a patients susceptibility to gastrointestinal d orders are also an object of the invention. It is y t another object of the present invention to provide methods of identifying defensin peptides. These and other objects will become apparent through a reading the detailed description and attached claims. Brief Description of the Drawings Figure 1 is a nucleotide sequence comparison of the 5' portion of cDNAs encoding rabbit defensin-1, rabbit defensin-2, human defensin-1 and human defensin 3. Short gaps were included to aid sequence comparison and were considered as mismatches when calculating percentage identity. The sequences for human defensin-1 (Daher, et al., Proc Natl Acad Sci USA 85: 7327-7331 (1988); Mars et al., Blood 71: 1713-1719 (1988) and human defensin-3 (Daher, et al., Proc Natl Acad Sci USA 85: 7327-7331 (1988); Wiedemann, et al. , Leukemia 3 : 227-234 (1989) are identical in the region presented. The sequences for rabbit defensins are from Ganz, et al., J Immunol 143: 1358- 1365 (1989) . Vertical lines denote identical sequences in all four cDNAs. The percentages in the right margin indicate nucleotide identity within the corresponding row. The putative initiating methionine codons are shown in bold, and the nucleotides encoding the putative signal sequence are underlined. The nucleotides corresponding to oligonucleotide probe, DS'oliαo. are overlined. Figure 2 sets forth the nucleotide sequence of HG2-3e, a genomic clone containing the human defensin 5 gene and flanking sequences. Figure 2A provides a partial restriction enzyme map of the 2.9kB EcoRl fragment, HG2-3e, that encodes human defensin 5 (Eco = EcoRl, Xho = Xhol, Xba = Xbal, Hin = Hindlll) . Hash marks equal 100 base pairs. The thickened lines shows the position of two exons. The arrows indicate the sequencing strategy used to analyze this clone. Figure 2B provides the nucleotide sequence of HG2-3e with numbering in reference to the first nucleotide adjacent to the EcoRl site. Exon sequences are shown in uppercase lettering and deduced amino acid sequence of the coding region is shown in three letter code. The TATA box is underlined and the CAAT box is double underlined. The consensus splice junction residues are shown in bold. The polyadenylation signal is boxed. Figure 3 is data resulting from PCR analysis of possible expression of the human defensin 5 gene in 8 human tissues. F ure 3A shows the results of a PCR reaction using cDNA from eight tissues and genomic DNA as templates. Two primers used in the PCR reaction were chosen from potential open reading frames (ORF) of the genomic sequence. HNP63s was a sense oligonucleotide from the upstream ORF, and HSIA261a was an antisense oligonucleotide from the downstream ORF. Pools of lambda phage cDNA from respective human tissues were used as PCR templates. Included as a control was human genomic DNA as a template. A standard protocol for amplification was used. Amplification products were size fractionated in a 3% agarose gel. A band of ca. 1.2 kB was seen in the genomic DNA sample, consistent with amplification across the intron. A band of 230 nucleotides was seen in the small intestine sample. No bands were seen in the other cDNA samples. Figure 3B shows a control amplification using alpha-tubulin primer pairs HTUBs and HTUBa to demonstrate the presence of adequate cDNA template from all tissues. Figure 3C is a filter hybridization of the amplification products from 3A with a probe (pSI25-3'Mbo2) consisting of nucleotides +121 to +450 of the defensin 5 cDNA under conditions of high stringency (final wash 65°C, 0.1X SSC, overnight exposure) . Figure 4 sets forth characterization of the human defensin 5 cDNA. Figure 4A is a Southern blot hybridization of 4 lambda gtll phage inserts isolated from a human small intestine cDNA library r^obed with D5' olicro. Final washes in 2X SSC were at the indicated temperatures. Figure 4B is a partial sequence of four clones shown in Figure 4A in the region corresponding to the probe. Nucleotides identical to the probe are represented by ":•'. Figure 4C provides the nucleotide sequence of human defensin 5 cDNA. The sequence represents the composite from the sequences of twr lambda cDNA clones (S.I. 25: nucleotides -10 to +415; S.I.34: nucleotides - 19 to +413) and two clones from primer extension/RACE PCR (pDJ117-4 and pDJ117-5: -19 to -40), and the putative initiating methionine codon is assigned to +1 to +3. The deduced amino acid sequence of the open reading frame is indicated in a single letter code. The polyadenylation addition signal is boxed. Figure 4D is a Southern blot hybridization of human genomic DNA probed with pSI25-3'Mbo2, a segment of human defensin 5 cDNA 3' to the Mbo2 site (nucleotides +121 to +450) . The filter was the same as that used in Figure 2B following stripping of the probe. Hybridization was in 50% formamide/5X SSC at 42°C, and the high stringency wash was in 0.1X SSC at 65°C for 30 minutes. The autoradiographic exposure was 14 days. Figure 5 is a northern blot hybridization of defensin expression in human tissue. In Figure 5A total RNA (lOμg) from adult human small intestine was size fractionated in a standard formaldehyde/agarose gel, capillary blotted to a nylon membrane, and probed with a defensin 5 oligonucleotide probe. The condition of stringency for hybridization and final wash were identical to those used in the in situ hybridization experiments described in Example 8. The size markers correspond to RNA standards from a parallel lane. The autoradiographic exposure was 2 days. Figure 5B is a northern blot of polyadenylation enriched RNA from 8 adult human tissues which was hybridized and washed in the same solution as in Figure 5A. The exposure was 10 days. The blot was subsequently used in the positive control experiments shown in Figures 5B and 5D. The exposure was 3 days. Figure 5D is a hybridization of the same northern blot as in Figure 5A with the antisense signal sequence oligonucleotide Sig68a. Bands appear in the lung and placenta lanes. The exposure was 10 days. Figure 6 is a comparison of deduced amino acid sequence of human preprodefensin 5 and 6 and the putative mature defensin 5 and 6 with known defensin family members. The deduced amino acid sequence of six preprodefensins are from published cDNAs. Cationic residues in human preprodefensin 5 are indicated by "+", and anionic residues by » -••. Residues identical to those of preprodefensin 5 are indicated by ":" in the human (Daher, et al., Proc Natl Acad Sci USA J35_: 7327-7331 (1988); Mars et al.. Blood 71: 1713-1719 (1988); Wiedemann et al.. Leukemia 3_: 227-234 (1989), rabbit (Ganz et al., J Immunol143: 1358-1365 (1989) and mouse (Ouellette and Lualid, J Biol Chem 265: 9831-9837 (1990) sequences. Human preprodefensins 1 and 3 are identical except for the single amino acid indicated, and the two rabbit sequences are identical except at position 2. The amino terminal residues of the human defensin 1 and 3, and rabbit defensin 1 and 2 are indicated with delta, based on available peptide data (Selsted, et al., J Biol Chem 258: 14485-14489 (1983); Selsted, et al., J Biol Chem 26f: 4579-4585 (1985); Selsted, et al. J Clin Invest 7_6: 1436-1439 (1985) . No peptide data is yet reported for defensin 5, 6 or mouse cryptdin, and the amino terminus indicated is speculation based on cleavage of two residues from the conserved cationic amino acid in the propeptide as in the other defensins. Short gaps (indicated by "-") were included in the sequences to aid in alignment. A consensus sequence for reported preprodefensins is presented, where an upper case letter denotes identity in all 6 sequences and lower case letters are conserved in 4 (or 5) of the 6. Figure 7 is the primary sequence of mature defensin peptides from five mammalian species. The format is similar to that presented previously (Hill et al., Science 251: 1481-85 (1991); Lehrer et al, J Virol 5_4: 467 (1991). Solid boxes indicate sequence identity from published sequence data (Selsted, et al. , J Biol Chem 258: 14485-14489 (1983); Selsted, et al., J Biol Chem 160: 4579-4585 (1985); Selsted, et al. J Clin Invest 76 . : 1436-1439 (1985) Selsted and Harwig, Infect Immun 5_5: 2281-2286 (1987); Singh et al., Bioch Biophys Res Commun 155: 524-529 (1988); Eisenhauer et al., Immun 57 . : 2021- 2027 (3989); Ouellette et al. , J Cell Biol 108: 1687-1695 (1989); Wilde et al., J Biol Chem 264: 11200-11203 (1989), and hashed boxes indicate near perfect consensus. The amino terminal residues of human defensin 5 and mouse cryptdin are underlined to indicate that they are based on cDNA analysis, not peptide data. Detailed Description of the Invention The present invention provides substantially pure polypeptides useful as gastrointestinal antimicrobial and anti- inflammatory agents. The term "antimicrobial" as used herein refers to killing microorganisms or suppressing their multiplication and growth. The term "anti-inflammatory" as used herein refers to inhibition of one or more of the indications associated with inflammation including vasodilation of local blood vessels with consequent excess local blood flow, increased permeability of the capillaries with leakage of large quantities of fluid into the interstitial space, clotting of the fluid in the interstitial space, migration of large numbers of granulocytes and monocytes into the tissue and swelling of the tissue cells. By "substantially pure" as used herein is meant greater than 50% of the material in a composition consists of the desired peptide. Sequences encoding this class of defensin polypeptides were identified based on the observation that the sequences of the 5' portion of the mRNA encoding human and rabbit myeloid-derived defensins have significant nucleotide similarity (Figure 1) . Thus in accordance with methods of the present invention a probe may be constructed based upon evolutionarily-conserved sequences. In preferred embodiments of the present invention a probe ( D 5 , o l i g o ) h a v i n g t h e s e q u e n c e CTTGCTGCCATTCTCCTGGTGGCCCTGCAGGCCCAGGCTGAGC (SEQ ID NO:35) was used to screen a population of clones to identify novel defensin peptides. In preferred embodiments of the present invention human genomic and cDNA libraries were screened using the D5' oligo probe and a number of clones were isolated. Hybridization and partial sequence analysis demonstrated that within these identified clones were previously characterized myeloid derived defensin sequences as well as new defensin related sequences. Two clones expressing such new defensin related sequences were extensively characterized and found to contain genes selectively expressed in Paneth cells of the small intestine. These Paneth cell-derived defensins are designated human defensin 5 and human defensin 6 and are referred to herein as gastrointestinal defensin peptides. Other gastrointestinal defensin peptides may similarly be identified using these methods. The genomic DNA sequence of Defensin 5 is set forth in Figure 2. The cDNA sequence and deduced amino acid sequence of Defensin 5 are set forth in Figure 4. The primary amino acid sequence of mature defensin 5 peptide is set forth in Figure 7. Comparison of the defensin 5 genomic (Figure 2) and cDNA (Figure 4) sequences indicate that the gene as two exons separated by an intron of 994 nucleotides. The nucleotide sequence of the exons in the genomic clone are in complete agreement with those in the cDNA sequence. There are consensus sequences for splice junctions (Figure 2, bold) and polyadenylation (Proudfoot and Brownlee, Nature 263: 211-214 (1976) (Figure 2, boxed). Approximately 1.4 kB of 5' flanking region of this gene was sequenced (Figure 2) . There is a TATA box at nucleotides 1328-1334, 24 nucleotides upstream from the 5' terminur? of the two most extended cDNAs identified by RACE- PCR (Figur underlined) . A CAAT box is seen 87 nucleotides upstream fio the termini of the extended cDNAs, at position 1267-1271 (Figure 2, double underlined). The cDNA sequence (Figure 4) suggests that the mature messenger RNA encoding defensin 5 is 449 nucleotides long, in addit ' ->n to the polyadenylate tail, which is consistent with the northern blot data (Figure 5) . The cDNA sequence contains an open reading frame of 94 codons in length from the first ATG codon (nucleotides +1 to +3) . The context of the methionine codon (CAGCCATGA) is identical to that found in the other two human defensin cDNAs, and is consistent with a favorable translation start sequence (Kozak, J Cell Biol 115: 887-903 (1991) . The nucleotide sequence encoding the putative signal sequence is 95% identical to the previously cloned human defensin cDNAs, while the nucleotides enco d ing the remainder of the putative coding region are only 36% identical, consistent with previous observations in the defensin family. Comparison of the deduced amino acid sequences of defensin 5 cDNA with the previously reported preprodefensins shows significant similarity with respect to size and charge distribution (Figure 6) . The carboxyl and amino termini of the putative mature defensin 5 peptide was inferred from patterns emerging from analysis of two rabbit and two human defensins where peptide and cDNA data are available. An in-frame stop codon follows the last residue of all of the peptides. The amino terminal amino acid of the mature peptide is two residues from a conserved cationic amino acid in the putative prepropeptide (Figure 6) . However, sequence comparison to other defensins shows primary structure conservation is not readily predictable by tissue source or species of origin (Figure 7) . The cDNA and deduced amino acid sequence of Defensin 6 is set forth in SEQ ID NO:6 and 7 respectively. The predicted primary amino acid sequence of mature defensin 6 peptide is set forth in Figure 7. The deduced amino acid sequence of defensin 6 cDNA has features similar to defensin 5 and the previously reported preprodefensins (Figure 6) . One notable distinction of preprodefensin 6 from the others is the addition of seven amino acid residues at positions 28-33 from the amino terminus. This segment is part of the putative propeptide region, a region that is important in post- translational trafficking and processing in many other peptides systems. Like other defensins, an in-frame stop codon follows the predicted carboxy-terminus, and a cationic propeptide residue is positioned 2 residues from the predicted amino terminus. The gastrointestinal defensin peptides of the present invention, depending on the pH of the environment, if suspended or in solution, or of its environment when crystallized or precipitates, if in solid form, may be in the form of pharmaceutically acceptable salts or may be in neutral form. The free amino groups of the protein are of course, capable of forming acid addition salts with, for example, organic acids such as hydrochloric, phosphoric, or sulfuric acid or with organic acids such as, for example, acetic, glycolic, succinic, or mandelic acid. The free carboxyl groups are capable of forming salts with bases, including inorganic bases such aε sodium, potassium or calcium hydroxides, and such organic bases as pi id , glucose , trimethyi ^ mine, choline and caffeir.-. _n addition, he protein may be modified by combination with other biological materials such as lipids and saccharides, or by side chain modification such as acetylation of amino groups, phosphorylation of hydroxyl side chains, or oxidation of sulfhydryl groups. Modifications of gastrointestinal defensin peptides are included within the scope of the definition, so long as the biological activity is retained. By biological activity is meant among other things, antimicrobial and/or anti- inflammatory activity. Finally it is understood that minor modifications of gastrointestinal defensin peptides may result in proteins which have substantially equivalent or enhanced biological activity as compared to the sequences set forth in SEQ ID NO: 5 and SEQ ID NO:7. These modifications may be deliberate, as through site-directed utagenesis, or may be accidental such as through mutation in hosts which are gastrointestinal defensin peptide producers. All of these modifications are included as long as the biological activity is retained. The defensins generally retain certain conserved critical residues of defensin peptides include 6 cysteines which participate in disulfide bonds, arginine -6, glutamic acid-14 and glycine-24. Other residues are believed to be key in dimeric quaternary structure: cysteine-5, glycine-18, cysteine-20, e ~ - hydrophobic residues at positions 22 and 28. Defensins 5 a 6 have conservation of all of these critical residues. Based on these sequence similarities, the biological activities, especially antimicrobial activities, of defensin 5 and 6 are believed to echo the biological activities of other defensin peptides. Furthermore, due to the localization of these gastrointestinal defensin peptic s and the observed increased concentration of gastrointestinal defensin peptides in the gastrointestinal tract of patients suffering from inflammatory bowel syndrome, these defensins are believed to be related to the modulation of gastrointestinal inflammation. Experiments using PCR (Figure 3A) and northern blot analysis (Figure 5A and 5B) indicate that the defensin 5 gene is limited in its tissue expression. The specific small intestinal cell expressing the defensin 5 gene is the Paneth cell, based on in situ histochemical data. Similarly, defensin 6 is localized in the Paneth cells. The specific lineage of Paneth cells and their physiological role are not well defined (Sandow and Whitehead, Gut .20: 420-431 (1979) . Paneth cells are found throughout the bowel but are especially abundant in the small intestinal ileum (Hertzog, Am J Pathol .13: 351-358 (1937) . The cells have abundant rough endoplasmic reticulum, an elaborate golgi apparatus and large secretory vesicles typical of a secretory cell (Trier, J Cell Biol 18: 599-620 (1963); Benke and Moe, J Cell Biol 22: 633-652 (1964) . Metaplasia of these cells has been seen in a variety of pathological conditions in humans (Geller and Thung, Arch Pathol Lab Med . 107 . : 476-479 (1983), including inflammatory bowel disease (Paterson and Watson, Am J Pathol 3_8: 243-249 (1961) , Several lines of evidence suggest these cells have a role in antimicrobial defense. Paneth cells have been shown to express tumor necrosis factor mRNA (Keshav et al., J Exp Med 171: 327-332 (1990) and to contain lysozyme (Paterson and Watson, Amer J Pathology 3J5: 243-249 (1961); Erlandsen et al., J Hiεtochem Cytochem .22!: 401-413 (1974); Klockars and Reitamo, J Histochem Cytochem 2_3: 932-940 (1975) ; Peeters and Vantrappen, Gut 16_'. 553-558 (1975) . The lysozyme is localized to secretory granules in these cells (Deckx et al., Biochem Biophys Acta 139: 204-207 (1967); Peeters and Vantrappen, Gut .16_: 553-558 (1975) , and various stimuli have been shown to effect degranulation of these cells (Klockars and Reitamo, J Hiεtochem Cytochem 2J3 . : 932-40 (1975) ; Peeters and Vantrappen, Gut !_____ . : 553-558 (1975); Satoh et al., Digestion 3_4: 115-121 (1986); Satoh and Vollrath, Anat Embryol 173: 317-322 (1986); Satoh et al., Anatojn Rec 225: 124-132 (1989). Thus, these finding further substantiate the role of defensin 5 and 6 as antimicrobial and anti-inflammatory peptides. It is believed that other peptides identified using methods of the present invention which are localized to the Paneth cells will also exhibit antimicrobial and anti-inflammatory activity. Having described the DNA and amino acid sequence of defensin 5 (SEQ ID NO:4 and SEQ ID NO: 5) and defensin 6 (SEQ ID NO:6 and SEQ ID NO:7) it is believed these gastrointestinal defensin peptides or portions thereof may be prepared using modifications of any of numerous well known recombinant techniques such as those described in U.S. Patent #4,677,063 which patent is incorporated by reference as if fully set forth herein. By "portion thereof" as used herein is meant to refer to any portion of a peptide or nucleic acid of sufficient size to retain desired biological activities, and particularly antimicrobial and anti-inflammatory activity. For example, some preferred defensin peptide "portions" are the mature peptides set forth in SEQ ID NO: 22 or SEQ ID NO: 51. Other portions which retain biological activity are also envisioned by the present invention. Briefly, most of the techniques which are used to transform cells, construct vectors, extract messenger RNA, prepare cDNA libraries, and the like are widely practiced in the art, and most practitioners are familiar with standard resource materials which describe specific conditions and procedures. However, for convenience, the following paragraphs may serve as a guideline. Procaryotes most frequently are represented by various strains of E. coli . However, other microbial strains may also be used, such as Bacilli , for example, Bacillus subtil is , various species of Pseudomonas , or other bacterial strains. In such procaryotic systems, plasmid vectors which contain replication sites and control sequences derived from a species compatible with the host are used. In one such "expression system" for example, E. coli is transformed using a derivative of pBR322, a plasmid derived from an E. coli species by Bolivar, et al., Gene 2_: 95 (1977). pBR322 contains genes for ampicillin and tetracycline resistance and thus provide additional markers which can be either retained or destroyed in constructing the desired vector. Commonly used procaryotic control sequences include promoters for transcription initiation, optionally with an operator, along with ribosome binding site sequences, include such commonly used promoters as the beta-lactamase (penicillinase) and lactose (lac) promoter systems (Chang, et al., Nature 198: 1056 (1977)) and the tryptophan (trp) promoter system (Goeddel, et al., Nucleic Acids Res 8 : 4057 (1980)) and the lambda derived P L promoter and N-gene ribosome binding site (Shimatoake, et al., Nature 292: 128 (1981)). In addition to bacteria, eucaryotic microbes, such as yeast may also be used as hosts. Laboratory strains of Saccharomyces cerevisiae , Baker's yeast, are most used although a number of other strains are commonly available. While vectors employing the 2 micron origin of replication are illustrated, Broach, J.R. , Meth Enz . 101: 307 (1983), other plasmid vectors suitable for yeast expression are known (see, for example, Steinchcomb, et al., Nature 282: 39 (1979), Tschempe, et al., Gene _1_Q_: 157 (1980) and Clark, L. , et al., Meth Enz 101: 300 (1983)). Control sequences for yeast vectors include promoters for the synthesis of glycolytic enzymes (Hess, et al., J. Adv Enzyme Req Z: 149 (1968); Holland, et al. Biochemistry 17: 4900 (1978)). Additional promoters known in the art include the promoter for 3- phosphoglycerate kinase (Hitzeman, et al., J. Biol . Chem 255: 2073 (1980)), and those for other glycolytic enzymes such as glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomeraεe, and glucokinase. Other promoters, which have the additional advantage of transcription controlled by growth conditions are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acidphosphataεe, degradative enzymes associated with nitrogen metaboliεm, and enzymes responεible for maltoεe and galactose utilization (Holland, ibid) . It is also believed terminator sequences are desirable at the 3' end of the coding sequences. Such terminators are found in the 3' untranslated region following the coding sequenceε in yeast-derived genes. Many of the vectors illustrated contain control sequenceε derived from the enolaεe gene containing plasmid peno46 (Holland, M.J., et al., J. Biol Chem 256: 1385 (1981)) or the LEU2 gene obtained from YEpl3 (Broach, J. , et al., Gene 8 . : 121 (1978)), however any vector containing a yeast compatible promoter, origin of replication and other control sequences is suitable. It is also of course possible to expresε geneε encoding polypeptideε in eucaryotic host cell cultures derived from multicellular organisms. See, for example, Tissue Cultures, Academic Presε, Cruz and Patterεon, editors (1973) . Useful host cell lines include VERO, HeLa cells, and Chinese hamster ovary (CHO) cells. In vivo expresεion of genes encoding polypeptides in eucaryotic hosts is also a feasible method of preparation of gastrointestinal defensin peptideε. Expression vectors for εuch cellε ordinarily include promoterε and control εequenceε compatible with mammalian cellε such as, for example, the commonly used early and late promoters from Simian Viruε 40 (SV 40) Fierε, et al., Nature 273: 113 (1978)), or other viral promoterε εuch aε thoεe derived from polyoma, Adenoviruε 2, bovine papilloma virus, or avian sarcoma viruseε. General aεpectε of mammalian cell hoεt εystem transformationε have been deεcribed e.g. by Axel; U.S. pat. No. 4,399,216. It now appearε, alεo that "enhancer" regionε are important in optimizing expression; these are, generally, sequenceε found upstream or downstream of the promoter region in non-coding DNA regions. Origins of replication may be obtained, if needed, from viral sourceε. However, integration into the chromoεome iε a common mechaniεm for DNA replication in eucaryoteε. Plant cellε are now available as hosts, and control sequence compatible with plant cells such as the nopaline εynthaεe promoter and polyadenylation εignal εequenceε (Depicker, A., et al., J. Mol Appl . Gen 1 : 561 (1982)) are available. Depending on the hoεt cell uεed, trc-nεformation is done using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as deεcribed by Cohen, .N., Proc Natl Acad Sci (USA) .69.: 2110 (1972), or methods described in Molecular Cloning: A Laboratory Manual (1988) Cold Springs Harbor Presε, could be used for procaryotes or other cells which contain εubεtantial cell wall barrierε. Infection with Agrobacterium tumefacienε (Shaw, CH. , et al., Gene 23: 315 (1983)) iε believed uεeful for certain plant cellε. For mammalian cellε without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb, Virology b2_. 546 (1978) can be uεed. Cellε may alεo be transformed in vivo by introducing a gene, incorporated in a vector, directly to cells in the walls of blood vesεelε uεing, for example, balloon catheter techniqueε. WO 90/11734 iεεued October 18, 1990. Transformations into yeast can be carried out according to the method of Van Solingen, P., et al., J Bact 130: 946 (1977) and Hsiao, CL. , et al. , Proc Natl Acad Sci (USA) 7_6: 3829 (1979). cDNA or genomic libraries can be screened using the colony hybridization procedure. Generally, each microtiter plate is replicated onto duplicate nitrocelluloεe filter paperε (S&S type BA-85) and colonieε are allowed to grow at 37°C for 14-16 hr on L agar containing 50 μg/ml Amp. The colonieε are lyεed and DNA fixed to the filter by εequential treatment for 5 min with 500 mM NaOH, 1.5M NaCl, and are waεhed twice for 5 min each time with 5X εtandard εaline citrate (SSC) . Filterε are air dried and baked at 80°C for 2 hr. The duplicate filters are prehybridized at 42°C for 6-8 hr with 10 ml per filter of DNA hybridization buffer (5xSSC, pH 7.05X Denhardt's εolution (polyvinylpyrrolidine, pluε Ficoll and bovine εerum albumin; lx=0.02% of each) , 50 mM εodium phoεphate buffer at pH 7.0, 0.02% SDS, 20 μg/ml Poly U, and 50 μg/ml denatured εalmon εperm DNA) . The εampleε can be hybridized with kinaεed probe under conditions which depend on the stringency desired. Typical moderately εtringent conditions employ a temperature of 42° C for 24-36 hr with 1-5 ml/filter of DNA hybridization buffer containing probe. For higher stringencies high temperatures and εhorter timeε are employed. Generally, the filters are washed four times for 30 min each time at 37°C with 2xSSC, 0.2% SDS and 50 mM εodium phoεphate buffer at pH 7, then are waεhed twice with 2xSSC and 0.2% SDS, air dried, and are autoradiographed at -70° C for 2 to 3 days. Construction of suitable vectors containing the desired coding and control sequenceε employs standard ligation and restriction techniques which are well under tood in the art. Iεolated plasmids, DNA sequenceε, or εyntheεized oligonucleotideε -re cleaved, tailored, and religated in the form deεired. Site εpecific DNA cleavage can be performed by treating the DNA with a εuitable reεtriction enzyme (or enzymeε) under conditions which are generally understood in the art, and the particularε of which are εpecified by the manufacturer of theεe commercially available restriction enzymes. See, e.g., New England Biolabε, Product Catalog. In general, about 1 μg of plasmid or DNA sequence is cleaved by one unit of enzyme in about 20 μl of buffer solution. Incubation times of about one hour to two hours at about 37° C are workable, although variations can be tolerated. After each incubation, protein can be removed by extraction with phenol/c- ..oroform, and may be followed by ether extraction, and the nucleic acid recovered from aqueouε fractionε by precipitation with ethanol followed by running over a Sephadex G-5 εpin column. If desired, size εeparation of the cleaved fragments may be performed by polyacrylamide gel or agarose gel electrophoresiε uεing εtandard techniqueε. A general deεcription of εize εeparationε can be found in Methods in Enzymology (1980) 65: 499-560. Restriction cleaved fragments may be blunt ended by treating with the large fragment of E. coli DNA polymeraεe I (Klenow) in the preεence of the four deoxynucleotide triphoεphates (dNTPε) uεing incubation times of about 15 to 25 min at 20° to 25° C in 50 mM Tris pH 7.6, 50 mM NaCl, 6 mM MgCl 2 , 6 M DTT and 5-10 μM dNTPs. The Klenow fragment fillε in at 5 sticky endε but chews back protruding 3' single strands, even though the four dNTPs are present. If deεired, selective repair can be performed by supplying only one of the, or selected, dNTPε within the limitationε dictated by the nature of the εticky ends. After treatment with Klenow, the mixture is extracted with phenol/chloroform and ethanol precipitated followed by running over a Sephadex G-50 spin column. Treatment under appropriate conditions with SI nuclease results in hydrolysis of any single-stranded portion. Synthetic oligonucleotides can be prepared by the trieεter method of Metteucci, et al. J Am Chem Soc 103: 3185 (1981)) or uεing commercially available automated oligonucleotide εyntheεizerε. Kinaεing of εingle εtrandε prior to annealing or for labeling iε achieved uεing an exceεε, e.g., approximately 10 units of polynucleotide kinase to 0.1 nmole substrate in the presence of 50 mM Triε, pH 7.6, 10 mM MgCl 2 , 5 mM dithiothreitol, 1-2 Mm ATP, 1.7 pmoles 7 32 P-ATP (2.9 mCi/mmole) , 0.1 mM spermidine, 0.1 mM EDTA. Ligationε can be performed in 15-30 μl volumeε under the following εtandard conditionε and temperature : 20 mM Triε-Cl pH 7.5, 10 mM MgCl 2 , 10 mM DTT, 33 μg/ml GSA, 10 mM-50 mM NaCl, and either 40 μM ATP, 0.01-0.02 (Weiεε) unitε T4 DNA ligaεe at 0° C (for "εticky end" ligation) or 1 mM ATP, 0.3-0.6 (Weiεε) unitε T4 DNA ligaεe at 14° C (for "blunt end" ligation) . Intermolecular "εticky end" ligations are usually performed at 33-100 μg/ml total DNA concentrations (5-100 mM total end concentration) . Intermolecular blunt end ligations (uεually employing a 10-30 fold molar exceεε of linkers) are performed at 1 μM total ends concentration. In vector construction employing "vector fragmentε", the vector fragment can be treated with bacterial alkaline phoεphataεe (BAP) in order to remove the 5' phoεphate and prevent religation of the vector. BAP digeεtionε can be conducted at pH 8 in approximately 150 mM Triε, in the preεence of Na+ and Mg+ 2 using about 1 unit of BAP per μg of vector at 60° C for about one hour. In order to recover the nucleic acid fragments, the preparation is extracted with phenol/chloroform and ethanol precipitated and desalted by application to a Sephadex G-50 εpin column. Alternatively, religation can be prevented in vectorε which have been double digested by additional restriction enzyme digeεtion of the unwanted fragments. For portions of vectors derived from cDNA or genomic DNA which require sequence modifications, site εpecific primer directed mutageneεiε can be used. This is conducted using a primer synthetic oligonucleotide complementary to a single stranded phage DNA to be mutagenized except for limited mismatching, representing the deεired mutation. Briefly, the εynthetic oligonucleotide is used as a primer to direct synthesis of a strand complementary to the phage, and the resulting double-stranded DNA is transformed into a phage- εuppcrting hoεt bacterium. Cultureε of the tranεformed bacteria are plated in top agar, permitting plaque formation from single cells which harbor the phage. Theoretically, 50% of the new plaques will contain the phage having, as a single strand, the mutated form; 50% will have the original εequence. The reεulting plaqueε can be hybridized with kinased synthetic primer at a temperature which permits hybridization of an exact match, but at which the miεmatcheε with the original εtrand are εufficient to prevent hybridization. Plaques which hybridize with the probe are then picked, cultured, and the DNA recovered. Correct ligationε for plaε id construction can be confirmed by first transforming a εuitable hoεt with the ligation mixture. Succeεεful tranεformantε are εelected by ampicillin, tetracycline or other antibiotic resistance or using other markers depending on the mode of plasmid construction, aε iε underεtood in the art. Plaεmidε from the tranεfor ants can then be prepared according to the method of Clewell, D.B., et al. Proc Natl Acad Sci (USA) §Z' 1159 (1969) , optionally following chloramphenicol amplification (Clewell, D.B., J. Bacteriol 110: 6670 (1972). The isolated DNA is analyzed by restriction and/or εequenced by the dideoxy method of Sanger, F. , et al. Proc Natl Acad Sci (USA) 7_4: 5463 (1977) as further described by Messing, et al., F. Supp. Nucleic Acids Res 9_: 309 (1981) , or by the method of Maxam, et al.. Methods in Enzymology .65: 499 (1980). For use as an antimicrobial or anti-inflammatory agent, gastrointeεtinal defenεin peptideε can be formulated into pharmacological compoεitionε containing an effective amount of gaεtrointeεtinal defenεin peptide and a uεual nontoxic carrier, such carriers being known in the art. The compoεitionε can be given via a route of adminiεtration suited to the form of the composition. Such compoεitionε are, for example, in the form of uεual liquid preparationε including εolutionε, εuεpenεionε, emulεionε and the like which can be given orally, intravenously, subcutaneouεly or intramuεcularly. The compoεition can be adminiεtered in an antimicrobially or anti-inflammatory effective amount, which will depend upon the patient, age, weight, and condition. Additionally, for treatment of microbial infection or gaεtrointestinal inflammation, endogenous expresεion of gaεtrointestinal defensin peptides may be induced in cells. The endogenous production of gaεtrointeεtinal defenεin peptide may be modulated by contacting cellε which expreεε the peptideε with a substance which regulates a gene coding for a gaεtrointeεtinal defenεin peptide. In particular, εubεtanceε which bind to or otherwiεe modulate the ordinary transcription of DNA coding for gastrointestinal defensin peptide or which bind to or otherwise inhibit the translation of mRNA coding for gaεtrointeεtinal defenεin peptide are uεeful to modulate gaεtrointestinal defensin production. Methods of identifying or deεigning effective substanceε, εuch aε polypeptideε, are known to thoεe εkilled in the art. Preferably εuch εubεtances bind to at leaεt a portion of one of the nucleic acid εequence defined in SEQ ID NO: 1, SEQ ID NO: 4 and/or SEQ ID NO: 6. More preferably a εubεtance such as a polypeptide binds to a cis- acting control element of SEQ ID NO: 1. Alternatively cells selected for expression of gastrointeεtinal defensin peptideε may be transformed in vitro or in vivo with DNA comprising a portion of a gastrointeεtinal defenεin peptide cDNA or genomic εequence as discuεεed previouεly. Cellε which are tranεformed in vitro may be introduced into a mammal by methodε familiar to thoεe εkilled in the art such as by performance of cellular grafts. In vivo tranεformation may alεo be accompliεhed by introduction of a recombinant vector deεcribed previously. WO 90/11734 isεued October 18, 1990. It is believed that the gastrointestinal defensin peptides may regulate the level of luminal microbiological flora. The high denεity of Paneth cellε near the distal ileum might contribute to a barrier reεtricting the abundance of inteεtinal microbiological flora to the colon. Second, the gaεtrointeεtinal defenεin peptides may be important in mucosal defense from microbial invasion. An effective hoεt defenεe εystem in the small bowel not requiring significant inflammation would preserve of the integrity of the villuε epithelium, and thereby maintain the critical function of absorbing nutrients. Gastrointeεtinal defenεin peptideε may contribute to εuch a defenεe. In some caseε, however, too little gastrointestinal defensin peptide iε preεent in the inteεtinal tract, leading to microbial infection, irritation and inflammation of the epithelium. In other caεeε, too much gaεtrointeεtinal defenεin peptide may be inappropriately produced in reεponεe to real or artificial stimuli. The epithelium of the gastrointestinal tract may become inflamed in responεe to the overproduction of defensin peptide. Thus, conditions such as diarrhea, inflammatory bowel disease, necrotizing enterocolitis and gastric ulcer diseaεe may reεult from underproduction or overproduction of theεe gastrointestinal defensin peptides. Diseased and abnormal conditions of the gaεtrointeεtinal tract may be diagnoεed by eaεuring the amount of defenεin peptide or mRNA coding for defenεin peptides present in a sample taken from a mammalian gastrointeεtinal tract and comparing the amount of peptide or mRNA present in the sample with the amount of peptide or mRNA present in a normal mammalian gaεtrointeεtinal tract. An abnormal amount of defensin peptide or mRNA coding for defensin peptides iε indicative of the likelihood of gaεtrointeεtinal disorders such as microbial infection or inflammation. Furthermore, the suεceptibility of a patient to a gaεtrointestinal disorder such as diarrhea, inflammatory bowel diεease, necrotizing enterocolitis, and gastric ulcer diseaεe can be predicted by methodε of the preεent invention. Theεe methods comprise the step of providing a DNA containing teεt εa ple from εaid human patient. Appropriate test sampleε εuch aε blood or tiεεue εamples are well known to those in the art. DNA from the DNA containing test εample may be amplified uεing an upstream probe having a sequence complementary to an upstream portion of a selected defensin sequence such as the sequenceε defined in SEQ ID NO: 1, SEQ ID NO: 4 or SEQ ID NO: 5. and a downstream probe which iε complementary to a downεtream portion of the εelected defenεin sequence by methods known in the art such as by polymeraεe chain reaction (PCR) , described in U.S. patent 4,386,202 issued to Mullis. In εome preferred embodimentε of the preεent invention an upεtream probe having a εequence as defined in SEQ ID NO: 48 and a downstream probe having a sequence as defined in SEQ ID NO: 39 are used. The term "upstream" is meant to refer to the position of DNA regionε relative to the 5' or 3' end of a nucleic acid εequence. Thoεe regionε on the 5' εide are said to be upstream by those skilled in the art. Likewiεe, downεtream iε meant to refer to the position of DNA regions at the 3' end of a nucleic acid sequence. Complementary, as the term is uεed herein refers to the stable duplex formation resulting from Watson-Crick base pairing. It should be understood by one skilled in the art that εome parameterε, εuch aε probe length, may vary depending upon the method of amplification εelected, however determination of optimal conditions is within the skill of a practitioner. Thereafter amplified DNA may be compared with DNA from a normal sample by any of a range of methods known in the art to identify one or more mutations of the amplified DNA aε compared to normal DNA whereby a mutation iε indicative of the likelihood that the patient haε increaεed suεceptibility to gaεtrointestinal disorders. A mutation can be any deviation of the nucleic acid εequence which iε not present in a normal, or wild type nucleic acid defensin sequence such as a base subεtitution, baεe deletion or baεe addition. In one embodiment of the preεent invention, a detectably labeled nucleic acid probe may be contacted with the teεt εample or amplified DNA from the test εample under hybridizing conditionε. The probe εhould be deεigned to be substantially complementary to wild type deiensin εequenceε, particularly in regionε known or εuεpected to carry common mutationε aεεociated with increased εuεceptibility to gaεtrointestinal disorderε. For example, probeε may be substantially complementary to at least a portion of a defensin sequence aε defined in SEQ ID N0:1, SEQ ID NO: 4 and SEQ ID NO:5. Hybridization of detectably labeled probes and the teεt εample occurε under hybridization conditions which will be apparent to those εkilled in the art. For example, hybridization can be performed at 42°C with 50% formamide, 0.1X SSC, 0.1% SDS, 3X SSC, 1% SDS, 5% dextran εulfate, denatured herring sperm DNA (100 μg/ml) . Alternatively hybridization may be performed at 65°C with 1% SDS, IM NaCl and 10% dextran sulfate. The parameters of these conditionε can of courεe be modified to optimize hybridization aε will be apparent to one skilled in the art. Detectably labeled probes which are substantially complementary to a selected wild type defensin εequence will hybridize to the wild type defensin sequence under hybridizing conditions and a signal will be detected. However, no signal will be detected in the absence of hybridization. The absence of hybridization iε diagnoεtic of the likelihood that the defenεin gene carrieε a mutationε and the increaεed likelihood that the patient may be εuεceptible to gaεtrointeεtinal disorders. Still other methods which may be used to compare amplified DNA with normal DNA in order to diagnose the εusceptibility of a patient to gaεtrointeεtinal diεorderε include direct εequencing εuch aε by modification of methodε described by Gyllensten and Erlich, Proc . Natl . Acad . Science U.S .A. 85.: 7652-7656 (1988); Innis, et al. Proc . Natl . Acad . Sci . U.S .A. 85 . : 9436-9440 (1988); McBride, et al., Clinical Chem . 3_5: 2196-2201 (1989); Ohara, et al., Proc . Natl . Acad . Sci . U.S .A. 86.: 5673-5677 (1989); Nakamaye, et al., et al. Proc . Natl . Acad . Sci . U.S.A. 16: 9947-9959 (1988); Stoflet, et al.. Science 239: 491-494 (1988) and Schowalter, et al., Genomics 6 : 23-32 (1990) . Multiplex PCR may alεo be uεeful for such diagnosiε in accordance with methodε εuch aε those described in Chamberlain, et al., Nucleic Acids Research 16: 11141-11156 (1988) and Chamberlain, et al., PCR Protocols : A Guide to Methods and Applications (Academic Preεε, Orlando, FL 1990) pp. 272-281. Mutationε of the DNA of a patient may alεo be detected by εubjecting amplified DNA/nor al DNA heteroduplexeε to enzymatic cleavage such as RNase A cleavage, Myerε, et al. Science 230: 1242-1246 (1985) , or chemical cleavage εuch aε by hydroxylamine and oεmium tetroxide (HOT) , Cotton, et al., Proc . Natl . Acad . Sci . U .S .A. j35_: 4397-4401 (1988) . Additional methodε which may be uεed to detect mutationε in a patient'ε defensin DNA sequence include denaturing gradient gel electrophoreεiε (DGGE) , Myerε, Nature 313: 495-498 (1985) and temperature-gradient gel electrophoresis, Rosenbaum and Riesner, Biophys . Chem . 26_: 235- 246 (1987) and Riesner, et al. Electrophoresis 10: 377-389 (1989) . Additional methods are discuεεed, for example, by Roεεiter and Caεkey, J. Biol . Chem . 268(22) : 12753-12756 (1990). Examples All reagentε were reagent grade from Sigma Chemicalε (St. Louis, MO) unlesε otherwiεe noted. Reεtriction enzymeε were purchaεed from Betheεda Reεearch Laboratorieε (Gaitherεburg, MD) or Boeringer Mannheim (Indianapoliε, IN) . Oligonucleotideε were made by the Nucleic Acid and Protein Core Facility, Department of Pediatricε, Univerεity of Pennεylvania School of Medicine. Oligonucleotide probeε were end labelled to a εpecific activity of ca. 10 7 DPM/pmol uεing 7~[ 32 P] ATP (300 Ci/mmol, DuPont, Wilmington, DE) and T4 polynucleotide kinaεe (Stratagene, La Jolla, CA) . Double-εtranded DNA probes were labelled to a specific activity of ca. 10 9 DPM/μg using α- [ 32 P]dCTP (800 Ci/mmol, DuPont) and T7 DNA polymeraεe (U.S. Biochemicalε, Cleveland, OH) , or uεing a thermal cycling method with fluoreεcently labelled primer oligonucleotideε and Taq DNA polymeraεe (Applied Biochemical Syεtemε, Foεter City, CA) . PCR productε, purified by glass milk adsorption (BiolOl, La Jolla, CA) were incubated in a standard fill-in reaction with T4 DNA polymerase (Pharmacia, Piscataway, NJ) and then subcloned by ligation to linearized, blunt-end plasmid DNA (Bluescript, Statagene) . Sequence data were analyzed using the DNA and protein analysis software MacVector (IBI, New Haven, CT) . Example 1 Probe construction The nucleotides encoding the signal εequence of rabbit defensin 1 and 2 (Ganz et al., J Immunol 143: 1359-1365 (1989) are 95% identical to that of human defensin 1 and 3(54/57 identical nucleotides. Figure 1) (Daher et al., Proc Natl Acad Sci USA 85_: 7327-7331 (1988); Mars et al., Blood 7_1: 1713-19 (1988); Wiedemann et al., Leukemia 3_: 227-234 (1989). The nucleotide identity dropε in other regionε, remaining low over the εegment encoding the mature peptides (53% nucleotide identity) . The overall identity between these two cDNA sequences averages about 62%. We designed a 43-baεe ol igonuc leotide having the εequence CTTGCTGCCATTCTCCTGGTGGCCCTGCAGGCCCAGGCTGAGC (D5 , oligo; SEQ ID NO: 35) based on the sequence within the region of identity (Figure 1) . We alεo conεtructed a double εtranded probe (CB587) which εpanε reεidueε -29 to +184 (numbering relative to the firεt nucleotide of the putative initiating codon) of the human defensin 1 cDNA (Daher et al., Proc Natl Acad Sci USA 85: 7327-7331 (1988) . About half of the DNA sequence of CB587 consiεts of the region of high conεervation, the other half iε more εpecific to human defensin 1 and 3. A search of the Gen-Bank data base (release 60.0) using the Univerεity of Wisconsin Genetics analysiε software (Devereux et al., Nucl Acids Res .12.: 387-395 (1984) found no sequenceε with εignificant εimilarity to these probes other than the known defensins . In addition the following probes were conεtructed: HNP19ε (5 ' untranεlated region) : CCCTGCCTAGCTAGAGGATTT (SEQ ID NO : 4 9 ) , HN P 3 6 7 a : ( 3 / unt r a n ε l a t e d r e g i o n ) TTCCCTGTAGCTCTCAAAGCAAAT (SEQ ID NO : 37 ) , and HNP317ε : (coding region) GAGACCCGTAAGACGACGACT (SEQ ID NO : 36) . Probeε were constructed on an automated DNA synthesizer (Applied Biosyεtemε Model 380B) . Example 2 Southern Blot Analyεiε of DNA digeεtε to detect defenεin family diversity Genomic DNA was digested to completion with restriction enzymes according to the recommendation of the supplier. DNA εampleε were εized fractionated by agaroεe gel electrophoreεiε, and blotted to nylon membranes using standard techniques (Reed and Mann, Nucl Acids Res 12: 7207-7221 (1985) ; Sambrook, et al., Molecular cloning: a laboratory manual Cold Spring Harbor, Cold Spring Harbor Laboratory Preεε (1989) . Hybridization with the [ 32 P]-5' end-labelled oligonucleotide probeε D5 , oligo (SEQ ID NO: 35), HNP19ε (SEQ ID NO: 49), HNP367a (SEQ ID NO: 37) and HNP317ε (SEQ ID NO: 36) was in 20% formamide, 5X SSC, IX Denhardt'ε and 1% SDS at 42°C. The double-εtranded probes CB587 and pSI25-3 , Mbo2 were labelled by random primer syntheεiε and hybridized in 25% (CB587) or 50% (pSI25-3 , Mbo2) formamide, 5X SSC, IX Denhardt's and 1% SDS at 42°C. The blots were waεhed for 1 hour at room temperature in 2X SSC and then in 2X SSC for 30 minuteε at a higher temperature of 55°C (HNP19ε, HNP367a, HNP317ε) , 58°C (CB587; SEQ ID NO: 38), 60°C (Dδ'oligo) or 63°C (Dδ'oligo). The final high εtringency wash for the blot hybridized with pSI25-3'Mbo2 was in 0.1X SSC at 65°C for 30 minutes. The moist filters were then subjected to autoradiography at -70°C in the presence of a Cronex Lightening Pluε intensifying screen (DuPont) . Blots were εtripped of probe by incubating in 0.5M NaOH/1.5M NaCl at room temperature for 20 to 40 minuteε, neutralized and then expoεed to film to document removal of prior εignal. In a Southern blot of the human DNA digeεt probed with D5'oligo multiple hybridization bandε of εimilar intenεity were obεerved in each of 4 laneε, and hybridization to high molecular weight DNA waε obεerved for εa ples digested with Sal-1 and Xho-1. The activity of these two enzymeε iε εenεitive to the methylation status of DNA, suggeεting that the probe iε hybridizing to a DNA region that iε highly methylated in thiε εample. Comparable results are seen when the final wash condition waε 2X SSC at 63°C. Qualitatively εimilar reεults were also observed when the blot was sequentially stripped of probe and rehybridized with CB587 or HNP19s. In contraεt to theεe obεervationε, hybridization of the εame blot to the HNP367a probe, corresponding to sequenceε in the 3'- untranεlated region of human defenεin 1 and 3 cDNAε yielded εingle bandε in these restriction digestions under similar conditionε of εtringency. Single bandε of hybridization were seen with the HNP317s probe from a portion of the condign region of human defenεin 1 and 3 cDNA. Theεe latter control experimentε indicated that the conditionε of εtringency uεed in thiε εeries of experiments were adequate to identify highly complementary sequenceε in genomic DNA. In a Southern blot of DNA from each of 7 εpecieε of animals digested to completion with Hindlll, and probed with CB587 several strong bands were seen in both human and monkey εampleε, and weaker bands were εeen in all of the other εpecieε. Very weak bandε were εeen in the mouse lane. The resultε indicate that human DNA containε numerouε εequenceε with εignificant εimilarity to a conεerved portion of defenεin mRNA, and the conεervation of εequence extendε between εpecieε. The conditionε uεed were 25% formamide/5X SSC at 42°C for the hybridization and 58°C in 2X SSC for the final waεh. Example 3 Screening of an Unamplified Human Genomic Library Liftε were made uεing Colony/Plaque Screen filterε (DuPont) , and the filterε were screened using standard techniques (Sambrook et al.. Molecular cloning: a laboratory manual Cold Spring Harbor. Cold Spring Harbor Laboratory Press (1989) . The standard conditionε for annealing and waεhing (Sambrook et al.. Molecular cloning: a laboratory manual Cold Spring Harbor. Cold Spring Harbor Laboratory Preεε (1989) were modified: 42°C, 20% formamide/5X SSC for hybridization and 55°C, 2X SSC for high εtringency waεh. Plaqueε were taken through 3-4 roundε of purification at progreεεively lower denεitieε. Phage DNA was isolated uεing Lambda-sorb (Promega, Madison, Wl) . Phage inεert DNA was subcloned by ligation into the multiple cloning site of Bluescript plasmid DNA. Nested deletions of plasmid inεert DNA for εequence analyεiε were created uεing an exonuclease III / mung bean nuclease reagent kit (Stratagene) according to the protocol of the εupplier. All reported εequenceε were obtained from both εtrandε of DNA. An unamplified human genomic library (kindly provided by Drε. M. Budarf and B. Emanuel (McDermid et al., Genomics 5 : 1-8 (1989)) was screened with Dδ'oligo as described in Example 2. From approximately four genome equivalentε of individual clones at a density of 2 X 10 4 /150mm plate, 35 relatively strong εignalε were obtained on εingle filterε. Twenty εignalε were taken to εecondary εcreen and twelve of these signalε remained positive and were plaque-purified. The twelve clones were categorized by a combination of restriction enzyme, hybridization and partial sequence analysis. All twelve genomic clones had insertε in the range of 12-15 kB and many contained more than one reεtriction fragment which contained a defenεin-related εequence. Hybridizationpropertieε to a panel of oligonucleotideε and partial εequence analyεiε indicated that five of these clones contained sequenceε conεiεtent with genes corresponding to bone marrow derived defensinε 1 and 3. Theεe clones were temporarily set aside. Partial characterization of εeveral other cloneε revealε that they alεo contained defenεin sequences. One clone, HG-2 was selected for in-depth characterization. An EcoRl reεtriction fragment that contained the defenεin-like εequence within thiε clone was isolated and the nucleotide sequence was determined (Figure 2) . Sequence analysiε revealed two open reading frames that appear to encode portionε of a putative preprodefenεin molecule. Example 4 PCR Amplification to determine tiεεue expreεsion of defensin genes PCR amplification waε carried out uεing standard protocols aε deεcribed (Saiki et al.. Science 239: 487-491 (1988) . Initial denaturation was at 94°C; 35 cycles of amplification were done by cycling one minute at 94°C, one minute at 55°C and two minutes at 72°C. Pools of cDNA for use as PCR templateε were prepared from plate lyεateε contain 3-5 x 10 5 phage. All human cDNA libraries used are commercially available (Clontech) , except from the small intestine which was obtained as a gift from L. Chan, Baylor University School of Medicine. For amplification of defenεin 5 related εequenceε an upstream sense primer waε chosen from one defensin-related open reading frame (HNP63S: TCGCCATCCTTGCTGCCATT; SEQ ID NO: 48) and the downεtream antiεenεe primer waε from the other (HSI261a: CGGCCACTGATTTCAC CAC; SEQ ID NO: 39) . Theεe primerε were choεen so the amplification product would include an intron when the template waε genomic DNA, a possible contaminant in a pool of cDNA. Figure 3A shows the results of a PCR reaction using cDNA from eight tissueε and genomic DNA aε templateε. A band of ca. 1.2 kB waε εeen in the genomic DNA sample, consiεtent with amplification acroεε the intron. A band of 230 nucleotideε waε seen in the small inteεtine εample. No bandε were εeen in the other cDNA εampleε. Similar reεultε were seen after amplification of defensin 6 related sequenceε. Control amplificationε from the cDNA templates used primer pairs (HTUBs: GATTGGCAATGCCTGCTGGGA; SEQ ID NO: 40 and HTUBa: CAGGTTGGTCTGGAATTCTGT; SEQ ID NO: 42) from the alpha-tubulin εequence (Cowan et al., Mol Cell Biol 3_: 1738- 1745 (1983) . Thiε amplification showed that all cDNA sampleε contained amplifiable template. (Figure 3B) . Subεequent hybridization of the amplification product to the pSI25-3 Mbo2 probe spanning most of the putative exon 2 under high stringency confirmed the authenticity of the amplified DNA, and suggeεted high relative abundance of this sequence in the small intestine cDNA pool. (Figure 3C) . On longer exposure there is some signal in fallopian tube and placenta. Similar resultε were obεerved for defenεin 6. A second control experiment uεing εimilarly deεigned primer pairε from the εequence of the human and defensin 1 and 3 cDNA yielded strong ethidium bromide staining band from the bone marrow cDNA and genomic DNA templates, but not from the εmall intestine or other cDNAs. Example 5 cDNA Cloning We εcreened 2.5 X 105 lambda cDNA cloneε of a human small intestine library with D5 , oligo (Chen et al., Science 238: 363-366 (1987) (generouε gift of Dr. Lawrence Chan, Baylor Univ.) . We obεerved 40 duplicate signals on primary screening. Twelve cloneε were taken through three rounds of plaque purification and isolation of phage DNA. Ten of these clones hybridized strongly with probeε DS'oligo and CB587, and within theεe ten, two classeε of cloneε were evident from hybridization patternε. Figure 4A εhows the hybridization pattern seen for two cloneε repreεentative of each claεε when probed with D5'oligo and then washed at progresεively higher temperature. The inεertε from theεe four cloneε were εubcloned and εequenced completely in both directionε. Sequence analyεiε indicated clone 34 was identical to clone 25 except that it extended 9 bases further at the 5' terminus (to nucleotide -19) , and clone 14 overlapped clone 30 in a similar fashion. Figure 4B εhows the sequence alignment of each clasε of εmall inteεtine cloneε with the probe, D5'oligo. Cloneε 1 and 2 had sequence which corresponded exactly to the oligonucleotide probe; clones 3 and 4 were 85% identical. Both of these two clasεeε of cloneε have an open reading frame, and the deduced amino acid εequence indicateε that each encodeε a novel putative preprodefenεin. Further hybridization experimentε using probeε from the 3 ' portion of theεe cloneε demonεtrates that the heterogeneity amongst these 10 iεolated cDNA clones appears to be limited to two clasεeε. Example 6 RACE-PCR To obtain additional nucleotide εequence of the 5'- segment of thir mesεage, a pool of εmall intestine cDNA was amplified using the rapid amplification of cDNA ends (RACE) technique. The RACE-PCR protocol was modified from Frohman (Frohman et al., Proc Natl Acad Sci (USA) J55: 8998-9002 (1988) . Total RNA (lOμg) and a poly-dT primer (In Vitrogen, San Diego, CA) waε used in the reverse transcription εtep. The DNA product was tailed with dATP and terminal tranεferaεe. Thiε DNA product waε then uεed aε a template in a PCR uεing the T7RACE (T. GACTCACTATAGTTTTTTTTTTTTTTT; SEQ ID NO: 43) primer- linker εequence aε an upstream primer, a commercially available T7 oligonucleotide (AATACGACTCACTATAG; SEQ ID NO: 44) and a down ream primer, HSI220a (GGACTCACGGGTAGCACAAC; SEQ ID NO: 45) , an antisenεe oligonucleotide from the putative coding region of the cDNA, aε PCR primerε according to the method deεcribed (Frohman et al., Proc . Natl Acad Sci (USA) j55_: 8998- 9002 (1988) . A diffuεe band of approximately 270 nucleotideε waε detectable by ethidium bromide εtaining (data not εhown) . The amplification product waε εubcloned into a plaεmid vector and three clones that extended to the methionine codon were analyzed. One of the cloneε extended from the downεtream primer and terminated at nucleotide -10, and may repreεent premature termination of the reverεe transcriptase. The εequence of the other two cloneε were identical, with extension from the downstream primer to nucleotide -40. The nucleotides +172 through -40 in this primer extension product correspond to contiguous nucleotides 1570-1359 in the genomic sequence of HG- 2 (Figure 2) . The composite cDNA sequence from these overlapping clones is presented in Figure 4C, with nucleotides obtained from the PACE-PCR studieε underlined. The εequence haε an open reading frame of 282 nucleotideε which encodeε a defensin-like prepropeptide. The 3' unique portion of this cDNA detects single bands of hybridization in Southern Blot analyεiε (Figure 4D) , consistent with a signal copy of this gene in the human genome. Example 7 Northern Blot Analyεiε RNA samples from small intestine and εeveral other human tiεεueε were εubjected to northern blot analysis using an oligonucleotide probe from this cDNA sequence (HSIA309a) Figure 5. Total RNA ( Clontech, Palo Alto, CA) was fractionated by agaroεe gel electrophoreεiε in the preεence of formaldehyde and blotted to nylon membraneε (Zetabind, Cuno, Inc. , Meriden, CT ) by the capillary technique (Sambrook et al.. Molecular cloning: a laboratory manual Cold Spring Harbor. Cold Spring Harbor Laboratory Press (1989) . RNA size standards (BRL) were run in parallel lanes. The filter containing poly-A enriched RNA was similarly prepared (Clontech) . Radioactively labelled DNA probes were hybridized to the immobilized RNA in 50% (v/v) formamide/5X SSC/5X Denhardt , ε/ 1% (w/v) SDS at 37°C, and waεhed in IX SSC/ 0.1% SDS at 55°C, the εame conditions of stringency as used in the in situ hybridization protocol (see below) . The oligonucleotide probes uεed in theεe experimentε were: SIG68A (GAGTGGCTCAGCCTGGGCCTGCAGGGCCACCAGGAGAATGG CAGCAAG; SEQ ID NO: 41), HSIA2628 (CTCTACAGACTCTGCTGTC GCTGAGCTTCCTAGATAGAAACCAAAGCA; SEQ ID NO: 46) and HSIA309a (TGCTTTGGTTTCTATCTAGGAAGCTCAGCGACAGCAGAGTCTGTAGAG; SEQ ID NO: 47) . Autoradiographic expoεure time at -70°C with an intenεifying εcreen waε 2 - 14 days. Blots were εtripped of oligonucleotide probe by incubation in 0.1X SSC/ 0.1% SDS at 65°C, and then re-exposed to film to document removal of prior signal. The HSIA309a probe recognized an abundant message of approximately 600 nucleotides in the small intestinal RNA (Figure 5A, lOμg total RNA, 3 day exposure) . Similar resultε were obεerved for defensin 6 probes. Under the same experimental conditionε, no meεεage was detected in pancreas, kidney, skeletal muscle, liver, lung, placenta, brain or heart samples (Figure 5B, 2μg poly-A RNA, 10 day exposure) , deεpite the preεence of intact RNA in theεe laneε aε demonεtrated by hybridization to a beta-actin probe (Figure 5C) . Again, εimilar reεults were observed for defensin 6. A control experiment uεing a εignal εequence oligonucleotide showed a defensin-related mRNA in the lung εample under very εimilar conditionε of εtringency (Figure 5D) . A much fainter εignal at thiε poεition (approximately 550 nucleotideε) of migration waε alεo detected in the placenta εample. The presence of a defenεin related εequence in human lung tissue is conεiεtent with prior northern blot analyεiε using a probe for defenεin 1 and 3 (Daher et al., Proc Natl Acad Sci USA 85: 7327-7331 (1988) , recent protein data from fetal lung tisεue (Bateman et al., J Biol Chem 266: 7524-7530 (1991) and inveεtigationε in our laboratory which led to the cloning of HNP-1 cDNA from a human lung library. Example 8 In εitu Hybridization The cellular localization of the defenεin meεεage was determined by in situ hybridization. Tiεεue εections of adult human intestinal ucosa were probed with senεe and antiεenεe 35 S-labelled oligonucleotideε. Strong εignal waε obεerved with the antiεenεe oligonucleotide probe, HSIA309a in epithelial cellε at the baεe of εmall inteεtinal cryptε in εectionε from the adult ileum. No εignal waε obεerved in parallel εectionε if the εenεe oligonucleotide probe, HSIA262ε waε uεed or if the sections were first treated with ribonuclease prior to hybridization with HSIA308a. Control experiments demonstrated that both the εenεe and antisense oligonucleotides were equally effective at hybridizing to pSI25-3 Mbo2 double stranded plasmid DNA under these experimental conditions. Crypt cells with similar if not identical morphological characteristicε εtained εtrongly with phloxine-tartrazine, a histochemical stain commonly uεed to detect Paneth cells (Lendrum, J Pathol Bacteriol 59.: 399-404 (1947) . Eosinophils present in the lamina propria of numerouε εmall inteεtinal εectionε alεo appeared to be weakly positive with the antisenεe oligonucleotide probe uεed in theεe experimentε, however the εignal waε not attenuated with pre-treatment with RNaεe and the sense oligonucleotide appeared equally positive (data not shown) . The simplest explanation from these control experiments iε that the εignal in theεe white cellε iε probably artifactual and not from hybridization to cellular RNA. No other cells in these εectionε hybridized to any of the probeε. Example 9 Antimicrobial activity of Defensin 5 Purified defensin 5 is tested on εeveral εtrainε of bacteria including Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa and Candida albicans to determine itε antimicrobial activity in vitro . Minimal inhibitory concentrationε were determined by incubating approximately 2.5 X 10 4 microbe in 0.25X TSB with 50, 25, 12.5, 6.25 or 3.125 μg/ml of the peptide. The minimal inhibitory concentration (μg/ml) should be approximately 3.125μg/ml. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Bevins, Charles L. Jones, Douglas E. (ii) TITLE OF INVENTION: Gastrointeεtinal Defenεin Peptides, cDNA Sequences, Methods for Production Uεe Thereof (iii) NUMBER OF SEQUENCES: 51 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Woodcock Waεhburn Kurtz Mackiewicz and Norriε (B) STREET: One Liberty Place - 46th Floor (C) CITY: Philadelphia (D) STATE: PA (E) COUNTRY: U.S.A. ' (F) ZIP: 19103 ω (V) COMPUTER READABLE FORM: ' (A) MEDIUM TYPE: Floppy diεk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Johnson, Philip S. (B) REGISTRATION NUMBER: 27,200 (C) REFERENCE/DOCKET NUMBER: CH-0219 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 215-568-3100 (B) TELEFAX: 215-568-3439 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2880 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1399..1572 I (ix) FEATURE: ■< ■» (A) NAME/KEY: CDS ° (B) LOCATION: 2552..2663 ' (ix) FEATURE: (A) NAME/KEY: TATA_signal (B) LOCATION: 1328..1334 (ix) FEATURE: (A) NAME/KEY: CAAT_εignal (B) LOCATION: 1267..1271 (ix) FEATURE: (A) NAME/KEY: misc_εignal (B) LOCATION: 1569..1576 (ix) FEATURE: (A) NAME/KEY: misc_signal (B) LOCATION: 2539..2549 (ix) FEATURE: (A) NAME/KEY: polyA_signal (B) LOCATION: 2770..2775 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: CAAATATAGA GACTCTCCAA GGGCCCACTG AGCCCCAAAG GATTTGGATC AAATATGGTG 60 ATATTATGGA AATATGTAGT AATATCTTAA AAATGTGTAA GATATAGTCT CTTTTTTTTT 120 TTTTTTAAGA GAAGGGGTCT CACTATGTTT TTAGGCTGGT ATCoAACTCC TGGTCTCCAG 180 TGATCCTCCC ACCTCAGCCT GTCAAATAGC TAGAAATATA GGCATGTACC ACCATGCTGG 240 CTTAAGATGC ATTCTTTGAC ACAGCAATTC TATTTCTATA AGTTTATCCA TATAGGTAAG 300 AGAACATATA TACAAGATAA TCACTGTAAC TTTACTTATT ACTGCAAAAG TTTAAAAATA 360 * y- y ACCAAATTGT AATAATTTTA TAATATTTTA TCAGTACAAA AAATAAGTGA TGGCATATAC 420 ' AAACCCTGGG ATAGTATAAG GCTATTAAAA TTATAATAGC ATTCCATGTA TTTTGATATA 480 CAAAGTGCCA ATGTTACAGG TGAAAAAAGC GAAGTGCAGA ATACTATGTG TAACTGTTAA 540 TAGTGATGGT TTGCTGGGTC AGAACTGAAG GCCTGGGGGT AGAAATGAGA GCTCATGACT 600 TCTACCTTTT GAATGTTGTT CCTTGTGCAT GATTTACAAT TTTCTAAAAC TAAAAAAAAA 660 ATCTCAGAAA GGGGCTGTAC GCACCTAAAT TACTTTGATA TTCCCCAAAG TGGAGAGAAG 720 TACCCGCTAC ACATTTTATG TGATGCATTC AGATCACACC AACTCCTTGA ACTAAATCCG 780 AATTTTTATT TTAATCTGAT AAACTTGGCC TACTATTTTA CTGAACTCAT TTCCCCTATA 840 GCCTGATAAG GTCATTGACC TCTCCATACT GGCACCAGCG GGAGACTACT CACCTCGAGA 900 TCTCAAAAGC CTCCTACATG AGGTTAGTAA TATCCCTGAA TCCTGCAATG AATTAACTCT 960 CTACTCCACT GGGTCCCAGG TCTGCCCCCA GAGAGTCATC CAGAGAGTAC CAGGGACCAT 1020 CTTCAGAAAA CAAGAGGCAT TTGATCCCCA AACTTCTTGA ATGAAAGCGC TGTTGTTTTT 1080 CTTTTTTGAA TATATAAAAG TAAATACTCA AGCAGATGGG AAACAGAACA GGATAGTAAT 1140 ACCCTTATCA TCATTAACAC CTTGGATCAA GAAGAGGCAT TAAGCATACA GACTCACGCT 1200 TTGATGAAAG CTGGGAGAAA GAGGAGCATC AAAGGGATCT CGAGAACAAA GGCAGTCCTT 1260 CCCCTCCCAA TCACATGCCC ACCTCCTCTC ACTGCAGCTT CTGTCTCAGG TCTTCTCCCA 1320 GCAGAGCTAT AAATCCAGGC TGACTCCTCA CTCCCCACAT ATCCACTCCT GCTCTCCCTC 1380 CTGCAGGTGA CCCCAGCC ATG AGG ACC ATC GCC ATC CTT GCT GCC ATT CTC 1431 Met Arg Thr lie Ala lie Leu Ala Ala lie Leu ' 1 5 10 • t CTG GTG GCC CTG CAG GCC CAG GCT GAG TCA CTC CAG GAA AGA GCT GAT 1479 ' Leu Val Ala Leu Gin Ala Gin Ala Glu Ser Leu Gin Glu Arg Ala Asp 15 20 25 GAG GCT ACA ACC CAG AAG CAG TCT GGG GAA GAC AAC CAG GAC CTT GCT 1527 Glu Ala Thr Thr Gin Lys Gin Ser Gly Glu Asp Asn Gin Asp Leu Ala 30 35 40 ATC TCC TTT GCA GGA AAT GGA CTC TCT GCT CTT AGA ACC TCA GGT 1572 lie Ser Phe Ala Gly Asn Gly Leu Ser Ala Leu Arg Thr Ser Gly 45 50 55 AGGAGACATC AATCTTGCAC ATCTGCAAAA TCTAGAAAAA AAGGATTGGA GAAAGGATCT 1632 GGAGTCAAGT GTGGAAAGGT CTACCTCACT TGAGTGACTT TACTTAATCT TCCTGGACCT 1692 TGATTTTCTC ATCTATAAAT TAATCAGTGA GAACCAAATA AATCTAAAAG ATTTTCTTTT 1752 TTCTAAGACT TTCAGCTCCA AGATATTTCT GTGAAATTTG CTACTTTTAA GATAGAAAGA 1812 GCTACACTGA CT^CTTCTTT GTAGATCTAA ATGGGCAGAC TTAGTTATAT AGAGAGTGTT 1872 TTACTTTGTC CATTGGAAAA GCTTTTAGAA CCTAGAGAGG AACCTATAGG TGTGTTTTGA 1932 TGTAGGCTAA TAGGCTTGAT TAAATCTTTC TACAATACAT CCTTAGATCA AAACATCATA 1992 TTGTGTCTCA TACATATACA CAATTATTGT TTGTCAATTA AAACAAGTAA ATATGTAAAA 2052 TGTTAAAAAA AAAAAAAAAA AAAAAAGGAG AGACAGAGAA TGAAGAATTT GAATTTGGAA 2112 AGTCTTCAAA GACTCCTTGA GCACCAAAGT ATTTGGTCCA TGACATTAGC ATGCACAATG 2172 CGGCATTTCA GAAACTGATT CAGGTGCTTT AGGGAGCCTT GTTAGGACCT GGAAATCACA 2232 CATGGAGGTC AAGATTAGGC GTGTGGATGA AGCAGAATGA AGAGTAGGTA ACCCTGAGGT 2292 TGAGAGGTAT ATTGTTGGAC CAGGGAGCAG GTAATAAATA CATCCTGGAT AGACTCACAT 2352 ■ * ** * ω GGGGAAAAAA ACTATGATCT TGCATGACTA ACACATAGCT AGTAAGATTT CTTGTCACTT 2412 ' ACGACAAAGA CATGAATTTT CTCCATCCTA ACATGACTGA TACAGTGTCT CTTATTTAGA 2472 CTATCTCAGT TAGTCTGGCT GTGCTTGTCC TTTTTCCCAC CTCCCTCGCT GTGCCTGACC 2532 CTCTCTTCTT TCCACAGGT TCT CAG GCA AGA GCC ACC TGC TAT TGC CGA ACC 2584 Ser Gin Ala Arg Ala Thr Cys Tyr Cys Arg Thr 1 5 10 GGC CGT TGT GCT ACC CGT GAG TCC CTC TCC GGG GTG TGT GAA ATC AGT 2632 Gly Arg Cys Ala Thr Arg Glu Ser Leu Ser Gly Val Cys Glu lie Ser 15 20 25 GGC CGC CTC TAC AGA CTC TGC TGT CGC TGAGCTTCCT AGATAGAAAC 2679 Gly Arg Leu Tyr Arg Leu Cys Cys Arg * 30 35 CAAAGCAGTG CAAGATTCAG TTCAAGGTCC TGAAAAAAGA AAAACATTTT ACTCTGTGTA 2739 CCTTGTGTCT TTCTAAATTT CTCTCTCCAA AATAAAGTTC AAGCATTAAA CTTAGTGTGT 2799 TTGACCTTTT TAATTTTCTT TTCTTTTTCC TTTTTTTTCT TTTGCTTTGT TATATGGTGG 2859 TTTGTATGGT TCCTTTGTAT T 2880 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein ' .1-* (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Arg Thr lie Ala lie Leu Ala Ala lie Leu Leu Val Ala Leu Gin 1 5 10 15 Ala Gin Ala Glu Ser Leu Gin Glu Arg Ala Asp Glu Ala Thr Thr Gin 20 25 30 Lys Gin Ser Gly Glu Asp Asn Gin Asp Leu Ala lie Ser Phe Ala Gly 35 40 45 Asn Gly Leu Ser Ala Leu Arg Thr Ser Gly 50 55 (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: Ser Gin Ala Arg Ala Thr Cys Tyr Cys Arg Thr Gly Arg Cys Ala Thr 1 5 10 15 Arg Glu Ser Leu Ser Gly Val Cys Glu lie Ser Gly Arg Leu Tyr Arg 20 25 30 Leu Cys Cys Arg 35 (2) INFORMATION FOR SEQ ID NO:4: • (i) SEQUENCE CHARACTERISTICS: ' (A) LENGTH: 424 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 10..294 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: ACCCCAGCC ATG AGG ACC ATC GCC ATC CTT GCT GCC ATT CTC CTG GTG 48 Met Arg Thr lie Ala lie Leu Ala Ala lie Leu Leu Val 10 GCC CTG CAG GCC CAG GCT GAG TCA CTC CAG GAA AGA GCT GAT GAG GCT 96 Ala Leu Gin Ala Gin Ala Glu Ser Leu Gin Glu Arg Ala Asp Glu Ala 15 20 25 ACA ACC CAG AAG CAG TCT GGG GAA GAC AAC CAG GAC CTT GCT ATC TCC 144 Thr Thr Gin Lys Gin Ser Gly Glu Asp Asn Gin Asp Leu Ala lie Ser 30 35 40 45 TTT GCA GGA AAT GGA CTC TCT GCT CTT AGA ACC TCA GGT TCT CAG GCA 192 Phe Ala Gly Asn Gly Leu Ser Ala Leu Arg Thr Ser Gly Ser Gin Ala 50 55 60 AGA GCC ACC TGC TAT TGC CGA ACC GGC CGT TGT GCT ACC CGT GAG TCC 240 Arg Ala Thr Cys Tyr Cys Arg Thr Gly Arg Cys Ala Thr Arg Glu Ser 65 70 75 CTC TCC GGG GTG TGT GAA ATC AGT GGC CGC CTC TAC AGA CTC TGC TGT 288 Leu Ser Gly Val Cys Glu lie Ser Gly Arg Leu Tyr Arg Leu Cys Cys 80 85 90 I CGC TGAGCTTCCT AGATAGAAAC CAAAGCAGTG CAAGATTCAG TTCAAGGTCC 341 Arg * 95 TGAAAAAAGA AAAACATTTT ACTCTGTGTA CCTTGTGTCT TTCTAAATTT CTCTCTCCAA 401 AATAAAGTTC AAGCATTAAA AAA 424 (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 94 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) UENCE DESCRIPTION: SEQ ID NO:5: Met Arg Thr lie Ala lie Leu Ala Ala lie Leu Leu Val Ala Leu Gin 1 5 10 15 Ala Gin Ala Glu Ser Leu Gin Glu Arg Ala Asp Glu Ala Thr Thr Gin 20 25 30 Lys <"" ■ ser Gly Glu Aεp Asn Gin Asp Leu Ala lie Ser Phe Ala Gly 35 40 45 Asn Gly Leu Ser Ala Leu Arg Thr Ser Gly Ser Gin Ala Arg Ala Thr 50 55 60 Cys Tyr Cys 7... g Thr Gly Arg Cys Ala Thr Arg Glu Ser Leu Ser Gly 65 70 75 80 ' •I * -. Val Cys Glu lie Ser Gly Arg Leu Tyr Arg Leu Cys Cys Arg * ° 85 90 ' (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 452 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 19..321 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: CCTCCAGCGA CCCTAGCC ATG AGA ACC CTC ACC ATC CTC ACT GCT GTT CTC 51 Met Arg Thr Leu Thr lie Leu Thr Ala Val Leu 1 5 10 I CTC GTG GCC CTC CAG GCC AAG GCT GAG CCA CTC CAA GCT GAG GAT GAT 99 ** Leu Val Ala Leu Gin Ala Lys Ala Glu Pro Leu Gin Ala Glu Aεp Aεp 15 20 25 ' CCA CTG CAG GCA AAA GCT TAT GAG GCT GAT GCC CAG GAG CAG CGT GGG 147 Pro Leu Gin Ala Lyε Ala Tyr Glu Ala Asp Ala Gin Glu Gin Arg Gly 30 35 40 GCA AAT GAC CAG GAC TTT GCC GTC TCC TTT GCA GAG GAT GCA AGC TCA 195 Ala Asn Asp Gin Asp Phe Ala Val Ser Phe Ala Glu Asp Ala Ser Ser AGT CTT AGA GCT TTG GGC TCA ACA AGG GCT TTC ACT TGC CAT TGC AGA 243 Ser Leu Arg Ala Leu Gly Ser Thr Arg Ala Phe Thr Cys His Cys Arg 60 65 70 75 AGG TCC TGT TAT TCA ACA GAA TAT TCC TAT GGG ACC TGC ACT GTC ATG 291 Arg Ser Cys Tyr Ser Thr Glu Tyr Ser Tyr Gly Thr Cys Thr Val Met 80 85 90 GGT ATT AAC CAC AGA TTC TGC TGC CTC TGAGGGATGA GAACAGAGAG 338 Gly lie Asn His Arg Phe Cys Cys Leu * 95 100 AAATATATTC ATAATTTACT TTATGACCTA GAAGGAAACT GTCGTGTGTC CCATACATTG 398 CCATCAACTT TGTTTCCTCA TCTCAAATAA AGTCCTTTCA GCAAAAAAAA AAAA 452 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 100 amino acidε (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: Met Arg Thr Leu Thr lie Leu Thr Ala Val Leu Leu Val Ala Leu Gin 1 5 10 15 Ala Lys Ala Glu Pro Leu Gin Ala Glu Asp Aεp Pro Leu Gin Ala Lys 20 25 30 Ala Tyr Glu Ala Asp Ala Gin Glu Gin Arg Gly Ala Asn Asp Gin Asp 35 40 45 Phe Ala Val Ser Phe Ala Glu Asp Ala Ser Ser Ser Leu Arg Ala Leu 50 55 60 Gly Ser Thr Arg Ala Phe Thr Cys His Cyε Arg Arg Ser Cyε Tyr Ser 65 70 75 80 Thr Glu Tyr Ser Phe Cys Cys Leu 100 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 202 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: GAGGCCTGGG TCAGAGGACT TCTGTCTGCC CTTCTCTGCT CATCCCGCAT AGCCTGAGGA 60 < 1 o TCTGTGCCTC CCAGCCATGA GGACCCTCGC TCTGCTTGCT GCCATTCTCC TGGTGGCCCT 120 l GCAGGCCCAG GCTGAGCACA TTTCAGTGAG CATCGATGAA GTCGTAGACC AGCAGCCCCC 180 ACAGGCAGAG GATCAGGACG TG 202 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 195 baεe pairε (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: GAGGCCTGGG TCAGAGGACT GCTGCCTGCC CCTCTCTGCT CATTCCATAC AGCCCTGTGC 60 CTCCCAGCCA TGAGGACCCT CGCTCTGCTT GCTGCCATTC TCCTGGTGGC CCTGCAGGCC 120 CAGGCTGAGC ACAGTTCAGT GAGCATCGAT GAAGTCGTAG ACCAGCAGCC CCCACAGGCA 180 GAGGATCAGG ACGTG 195 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 203 baεe pairε (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: υi AAGACCTGGG ACAGAGGACT GCTGTCTGCC CTCTCTGGTC ACCCTGCCTA GCTAGAGGAT 60 ' CTGTGACCCC AGCCATGAGG ACCCTCGCCA TCCTTGCTGC CATTCTCCTG GTGGCCCTGC 120 AGGCCCAGGC TGAGCCACTC CAGGCAAGAG CTGATGAGGT TGCTGCAGCC CCGGAGCAGA 180 TTGCAGCGGA CATCCCAGAA GTG 203 (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 203 baεe pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: AAGACCTGGG ACAGAGGACT GCTGTCTGCC CTCTCTGGTC ACCCTGCCTA GCTAGAGGAT 60 CTGTGACCCC AGCCATGAGG ACCCTCGCCA TCCTTGCTGC CATTCTCCTG GTGGCCCTGC 120 AGGCCCAGGC TGAGCCACTC CAGGCAAGAG CTGATGAGGT TGCTGCAGCC CCGGAGCAGA 180 TTGCAGCGGA CATCCCAGAA GTG 203 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 94 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: Met Arg Thr Leu Ala lie Leu Ala Ala lie Leu Leu Val Ala Leu Gin 1 5 10 15 Ala Gin Ala Glu Pro Leu Gin Ala Arg Ala Asp Glu Val Ala Ala Ala 20 25 30 Pro Glu Gin lie Ala Ala Asp lie Pro Glu Val Val Val Ser Leu Ala 35 40 45 Trp Asp Glu Ser Leu Ala Pro Lys His Pro Gly Ser Arg Lys Met Asn 50 55 60 Ala Cys Tyr Cys Arg lie Pro Ala Cys lie Ala Gly Glu Arg Arg Tyr 65 70 75 80 Gly Thr Cys lie Tyr Gin Gly Arg Leu Trp Ala Phe Cys Cys 85 90 (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 94 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: Met Arg Thr Leu Ala 1 Leu Ala Ala lie Leu Leu Val Ala Leu Gin 1 5 10 15 en Ala Gin Ala Glu Pro Leu Gin Ala Arg Ala Asp Glu Val Ala Ala Ala ) 20 25 30 I Pro Glu Gin lie Ala Ala Asp lie Pro Glu Val Val Val Ser Leu Ala 35 40 45 Trp Asp Glu Ser Leu Ala Pro Lys His Pro Gly Ser Arg Lys Met Asn 50 55 60 Asp Cys Tyr Cys Arg lie Pro Ala Cys lie Ala Gly Glu Arg Arg Tyr 65 70 75 80 Gly Thr Cys lie Tyr Gin Gly Arg Leu Trp Ala Phe Cys Cyε 85 90 (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 95 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: Met Arg Thr Leu Ala Leu Leu Ala Ala lie Leu Leu Val Ala Leu Gin 1 5 10 15 Ala Gin Ala Glu His Val Ser Val Ser lie Asp Glu Val Val Asp Gin 20 25 30 Gin Pro Pro Gin Ala Glu Asp Gin Asp Val Ala lie Tyr Val Lys Glu 35 40 45 His Glu Ser Ser Ala Leu Glu Ala Leu Gly Val Lys Ala Gly Val Val ' Cys Ala Cyε Arg Arg Ala Leu Cyε Leu Pro Arg Glu Arg Arg Ala Gly ' 65 70 75 80 Arg Cyε Arg lie Arg Gly Arg lie Hiε Pro Leu Cyε Cyε Arg Arg 85 90 95 (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 95 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: Met Arg Thr Leu Ala Leu Leu Ala Ala lie Leu Leu Val Ala Leu Gin 1 5 10 15 Ala Gin Ala Glu His lie Ser Val Ser lie Asp Glu Val Val Asp Gin 20 25 30 Gin Pro Pro Gin Ala Glu Asp Gin Asp Val Ala lie Tyr Val Lys Glu 35 40 45 His Glu Ser Ser Ala Leu Glu Ala Leu Gly Val Lys Ala Gly Val Val 50 55 60 Cys Ala Cys Arg Arg Ala Leu Cyr "eu Pro Leu Glu Arg Arg Ala Gly 65 70 75 80 Arg Cys Arg lie Arg Gly Arg lie His Pro Leu Cys Cys Arg Arg 85 90 95 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 93 amino acidε (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: Met Lyε Lys Leu Val Leu Leu Phe Ala Leu Val Leu Leu Gly Phe Gin 1 5 10 15 Val Gin Ala Glu Gin Pro Gly Glu Glu Asp Gin Ala Val Ser Val Ser Phe Gly Asp 35 40 45 Pro Glu Gly Thr Ser Leu Gin Glu Glu Ser Leu Arg Asp Leu Val Cys 50 55 60 Tyr Cys Arg Ser Arg Gly Cys Lys Gly Arg Glu Arg Met Aεn Gly Thr 65 70 75 80 Cyε Arg Lyε Gly Hiε Leu Leu Tyr Thr Leu Cyε Cyε Arg 85 90 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: w (A) LENGTH: 100 amino acidε ° (B) TYPE: amino acid ' (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: Met Arg Thr Leu Ala Xaa Leu Ala Ala lie Leu Leu Val Ala Leu Gin 1 5 10 15 Ala Gin Ala Glu Xaa Xaa Gin Xaa Xaa Xaa Asp Glu Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ser Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 55 60 Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Arg Xaa Xaa Xaa Cys Xaa Xaa 65 70 75 80 Xaa Glu Arg Xaa Xaa Gly Xaa Cys Xaa Xaa Gly Xaa Xaa Xaa Xaa Xaa 85 90 95 Xaa Cys Cys Xaa 100 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 amino acids (B) TYPE: amino acid υi (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: Ala Cyε Tyr Cyε Arg lie Pro Ala Cyε lie Ala Gly Glu Arg Arg Tyr 1 5 10 15 Gly Thr Cyε lie Tyr Gin Gly Arg Leu Trp Ala Phe Cys Cys (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: Cys Tyr Cys Arg lie Pro Ala Cys lie Ala Gly Glu Arg Arg Tyr Gly 1 5 10 15 Thr Cys lie Tyr Gin Gly Arg Leu Trp Ala Phe Cyε Cyε 20 25 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: ui (A) LENGTH: 30 amino acids oo (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: Asp Cys Tyr Cys Arg lie Pro Ala Cyε lie Ala Gly Glu Arg Arg Tyr 1 5 10 15 Gly Thr Cyε lie Tyr Gin Gly Arg Leu Trp Ala Phe Cyε Cys 20 25 30 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: Tyr Cys Ser Cys Arg Leu Val Phe Cys Arg Arg Thr Glu Leu Arg Val 1 5 10 15 Gly Asn Cys Leu lie Gly Gly Val Ser Phe Thr Tyr Cys Cys Thr Arg 20 25 30 Val UI (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: Ala Thr Cys Tyr Cys Arg Thr Gly Arg Cys Ala Thr Arg Glu Ser Leu 1 5 10 15 Ser Gly Val Cys Glu lie Ser Gly Arg Leu Tyr Arg Leu Cys Cys Arg 20 25 30 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: εingle (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: Val Cyε Tyr Cyε Arg Ser Arg Gly Cyε Lys Gly Arg Glu Arg Met Asn 1 5 10 15 Gly Thr Cys Arg Lys Gly His Leu Leu Tyr Thr Leu Cys Cys Arg • 20 25 30 σ. o (2) INFORMATION FOR SEQ ID NO:24: ' (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: Arg Arg Cys lie Cys Thr Thr Arg Thr Cys Arg Phe Pro Tyr Arg Arg 1 5 10 15 Leu Gly Thr Cys lie Phe Gin Asn Arg Val Tyr Thr Phe Cys Cys 20 25 30 (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: Val Val Cys Ala Cyε Arg Arg Ala Leu Cys Leu Pro Arg Glu Arg Arg 1 5 10 15 Ala Gly Phe Cys Arg lie Arg Gly Arg lie His Pro Leu Cys Cys Arg 20 25 30 Arg (2) INFORMATION FOR SEQ ID NO-?6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: Val Val Cyε Ala Cys Arg Arg Ala Leu Cys Leu Pro Leu Glu Arg Arg Ala Gly Phe Cys Arg lie Arg Gly Arg lie His Pro Leu Cys Cys Arg 20 25 30 Arg (2) INFORMATION FOR SEQ ID NO:27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown σ-- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: t l Gly lie Cys Ala Cys Arg Arg Arg Phe Cys Pro Aεn Ser Glu Arg Phe 1 5 10 15 Ser Gly Tyr Cys Arg Val Aεn Gly Ala Arg Tyr Val Arg Cyε Cyε Ser 20 25 30 Arg Arg (2) INFORMATION FOR SEQ ID NO:28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 amino acidε (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: Gly Arg Cys Val Cys Arg Lys Gin Leu Leu Cys Ser Tyr Arg Glu Arg 1 5 10 15 Arg lie Gly Asp Cys Lys lie Arg Gly Val Arg Phe Pro Phe Cys Cys 20 25 30 Pro Arg (2) INFORMATION FOR SEQ ID NO:29: (i) SEQUENCE CHARACTERISTICS: I (A) LENGTH: 33 amino acids o-. (B) TYPE: amino acid l*> (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: Val Ser Cys Thr Cys Arg Arg Phe Ser Cys Gly Phe Gly Glu Arg Ala 1 5 10 15 Ser Gly Ser (2) INFORMATION FOR SEQ ID NO:30 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30: Val Phe Cyε Thr Cyε Arg Gly Phe Leu Cyε Gly Ser Gly Glu Arg Ala 1 5 10 15 Ser Gly Ser Cys Thr lie Asn Gly Val Arg His Thr Leu Cys Cys Arg 20 25 30 Arg 0" (2) INFORMATION FOR SEQ ID NO:31: 4- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31: Val Thr Cys Tyr Cys Arg Arg Thr Arg Cys Gly Phe Arg Glu Arg Leu 1 5 10 15 Ser Gly Ala Cys Gly Tyr Arg Gly Arg lie Tyr Arg Leu Cys Cys Arg 20 25 30 (2) INFORMATION FOR SEQ ID NO:32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32: Cys Ser Cys Arg Thr Ser Ser Cys Arg Phe Gly Glu Arg Leu Ser Gly u 1 5 10 15 Ala Cyε Arg Leu Aεn Gly Arg lie Tyr Arg Leu Cys Cys 20 25 (2) INFORMATION FOR SEQ ID NO:33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single ( v D) ' TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33: Ala Cys Tyr Cys Arg lie Gly Ala Cys Val Ser Gly Glu Arg Leu Thr 1 5 10 15 Gly Ala Cys Gly Leu Asn Gly Arg lie Tyr Arg Leu Cys Cys Arg 20 25 30 (2) INFORMATION FOR SEQ ID NO:34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 amino acidε (B) TYPE: amino acid (C) STRANDEDNESS: εingle (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34: σ Xaa Xaa Cyε Xaa Cyε Arg Xaa Xaa Xaa Cyε Xaa Xaa Xaa Glu Arg Xaa • 1 5 10 15 Xaa Gly Xaa Cys Xaa Xaa Xaa Gly Xaa Xaa Xaa Xaa Xaa Cys Cyε Xaa 20 25 30 Xaa (2) INFORMATION FOR SEQ ID NO:35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 baεe pairε (B) TYPE: nucleic acid (C) STRANDEDNESS: εingle (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35: CTTGCTGCCA TTCTCCTGGT GGCCCTGCAG GCCCAGGCTG x- ^ - 43 (2) INFORMATION FOR SEQ ID NO:36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairε (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36: GAGACCCGTA AGACGACGAC T 21 (2) INFORMATION FOR SEQ ID NO:37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37: TTCCCTGTAG CTCTCAAAGC AAAT 24 (2) INFORMATION FOR SEQ ID NO: 38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 218 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38: CCCTGCCTAG CTAGAGGATC TGTGACCCCA GCCATGAGGA CCCTCGCCAT CCTTGCTGCC 60 ATTCTCCTGG TGGCCCTGCA GGCCCAGGCT GAGCCACTCC AGGCAAGAGC TGATGAGGTT 120 ' GCTGCAGCCC CGGAGCAGAT TGCAGCGGAC ATCCCAGAAG TGGTTGTTTC CCTTGCATGG 180 ∞ I GACGAAAGCT TGGCTCCAAA GCATCCAGGC TCAAGGAA 218 (2) INFORMATION FOR SEQ ID NO:39: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39: CGGCCACTGA TTTCACACAC 20 (2) INFORMATION FOR SEQ ID NO:40: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ TD NO:40: GATTGGCAAT GCCTGCTGGG A 21 (2) INFORMATION FOR SEQ ID NO:41: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 48 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41: GAGTGGCTCA GCCTGGGCCT GCAGGGCCAC CAGGAGAATG GCAGCAAG 48 (2) INFORMATION FOR SEQ ID NO:42: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42 CAGGTTGGTC TGGAATTCTG T 21 (2) INFORMATION FOR SEQ ID NO:43: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43: TACGACTCAC TATAGTTTTT TTTTTTTTTT 30 (2) INFORMATION FOR SEQ ID NO:44: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44 AATACGACTC ACTATAG 17 (2) INFORMATION FOR SEQ ID NO:45: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairε (B) TYPE: nucleic acid (C) STRANDEDNESS: εingle (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45: GGACTCACGG GTAGCACAAC 20 (2) INFORMATION FOR SEQ ID NO:46: (i) SEQUENCE CHARACTERISTICS: H (A) LENGTH: 48 baεe pairε (B) TYPE: nucleic acid (C) STRANDEDNESS: εingle (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46: CTCTACAGAC TCTGCTGTCG CTGAGCTTCC TAGATAGAAA CCAAAGCA 48 (2) INFORMATION FOR SEQ ID NO:47: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 48 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:47: TGCTTTGGTT TCTATCTAGG AAGCTCAGCG ACAGCAGAGT CTGTAGAG 48 (2) INFORMATION FOR SEQ ID NO:48: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: εingle (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48: t TCGCCATCCT TGCTGCCATT 20 (2) INFORMATION FOR SEQ ID NO:49: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 baεe pairε (B) TYPE: nucleic acid (C) STRANDEDNESS: εingle (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49: CCCTGCCTAG CTAGAGGATT T 21 (2) INFORMATION FOR SEQ ID NO:50: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (χϊ SEQUENCE DESCRIPTION: SEQ ID NO:50: CTCACTGCTG TTCTCCTCGT GGCCCTCCAG GCCAAGGCTG AGC 43 (2) INFORMATION FOR SEQ ID NO:51: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51: Thr Cys His Cys Arg Arg Ser Cys Tyr Ser Thr Glu Tyr Ser Tyr Gly 1 5 10 15 Thr Cys Thr Val Met Gly lie Asn His Arg Phe Cys Cyε Leu 20 25 30

Claims: What is claimed iε: 1. A εubεtantially pure, gastrointestinal defensin peptide comprising at least a portion of the amino acid sequence defined in SEQ ID NO:5. 2. A substantially pure, gaεtrointeεtinal defenεin peptide comprising at least a portion of the amino acid sequence as defined in SEQ ID NO:7. 3. A εubεtantially pure gaεtrointeεtinal defenεin peptide produced from at least a portion of the cDNA encoding a gastrointestinal defensin peptide, wherein said cDNA compriseε the DNA εequence defined in SEQ ID NO:4. 4. A εubεtantially pure gaεtrointeεtinal defenεin peptide produced from at leaεt a portion of the cDNA encoding a gaεtrointestinal defensin peptide, wherein said cDNA compriseε the DNA sequence defined in SEQ ID NO: 6. 5. A recombinant vector capable of expresεion in a εuitable expreεεion εyεtem compriεing a DNA εequence encoding an gaεtrointeεtinal defenεin peptide linked to control sequences compatible with said expreεεion εyεtem. 6. The vector of claim 5 wherein the DNA εequence compriεeε at leaεt a portion of the sequence defined by SEQ ID NO:4. 7. The vector of claim 5 wherein the DNA sequence compriεeε at leaεt a portion of the εequence defined by SEQ ID NO: 6. 8. A gaεtrointeεtinal defenεin peptide produced from the recombinant expreεsion vector of claim 6. 9. A gaεtrointeεtinal defenεin peptide produced from the recombinant expresεion vector of claim 7. 10. A contact diεinfectant compriεing an effective amount of a gaεtrointeεtinal defenεin peptide in a εuitable carrier. 11. The contact diεinfectant of claim 10 wherein the gaεtrointestinal defensin peptide has an amino acid sequence comprising at leaεt a portion of the εequence aε defined in SEQ ID NO:5. 12. The contact diεinfectant of claim 10 wherein the gaεtrointestinal defensin peptide haε an amino acid sequence comprising at least a portion of the sequence as defined in SEQ ID NO:7. 13. A pharmaceutical compoεition compriεing a gastrointestinal defensin peptide in a pharmaceutically acceptable carrier. 14. The pharmaceutical composition of claim 13 wherein the ga trointestinal defensin peptide comprises at least a portion of the sequence as defined in SEQ ID NO: 5. 15. The pharmaceutical composition of claim 13 wherein the gaεtrointeεtinal defenεin peptide compriεes at least a portion of the sequence as defined in SEQ ID NO:7. 16. A method of treating a microbial infection compriεing administering to a mammal suffering from a microbial infection an antimicrobially effective amount of a gastrointestinal defensin peptide. 17. The method of claim 16 wherein the gastrointeεtinal defensin peptide comprises at least a portion of the amino acid sequence defined in SEQ ID NO: 5. 18. The method of claim 16 wherein the gastrointestinal defensin peptide compriseε at least a portion of the amino acid sequence defined in SEQ ID NO: 7. 19. The method of claim 16 wherein the gastrointeεtinal defenεin peptide iε administered by expresεing the gaεtrointeεtinal defensin peptide endogenouεly. 20. The method of claim 18 wherein the gaεtrointeεtinal defenεin peptide iε expreεεed endogenouεly by tranεforming cellε in vivo with cDNA compriεing at leaεt a portion of the cDNA εequence defined in SEQ ID NO: 4. 21. The method of claim 18 wherein the gastrointestinal defensin peptide iε expreεεed endogenouεly by tranεforming cellε in vivo with cDNA compriεing at least a portion of the cDNA sequence defined in SEQ ID NO: 6. ' 22. The method of claim 20 wherein the step of tranεforming cellε further compriεeε uεing a recombinant vector which comprises said cDNA sequence operably linked to regulatory control sequences which are capable of effecting the expression of said coding sequence in said transformed cell. 23. The method of claim 21 wherein the step of transforming cells further compriseε uεing a recombinant vector which compriεes said cDNA sequence operably linked to regulatory control sequenceε which are capable of effecting the expreεεion of εaid coding sequence in εaid tranεformed cell. 24. A method of treating gaεtrointeεtinal inflammation compriεing adminiεtering to a mammal εuffering from gaεtrointestinal inflammation an anti-inflammatory effective amount of a gastrointeεtinal defenεin peptide. 25. The method of claim 24 wherein the gaεtrointeεtinal defenεin peptide compriεeε at leaεt a portion of the amino acid sequence defined in SEQ ID NO: 5. 26. The method of claim 24 wherein the gastrointestinal defensin peptide comprises at least a portion of the amino acid sequence defined in SEQ ID NO: 7. 27. The method of claim 24 wherein the gastrointestinal defensin peptide is administered by expreεεing the gaεtrointeεtinal defenεin peptide endogenouεly. 28. The method of claim 26 wherein the gastrointeεtinal defenεin peptide iε expreεεed endogenouεly by tranεforming cellε in vivo with cDNA compriεing at leaεt a portion of the cDNA sequence defined in SEQ ID NO: 4. -.9. The method of claim 27 wherein the gastrointeεtinal defenεin peptide iε expreεεed endogenouεly by tranεforming cells in vivo with cDNA comprising at least a portion of the cDNA sequence defined in SEQ ID NO: 6. 30. The method of claim 28 wherein the εtep of tranεforming cells further comprises using a recombinant vector which compriseε εaid cDNA εequence operably linked to regulatory control εequenceε which are capable of effecting the expreεεion of εaid coding sequence in said transformed cell. 31. The method of claim 29 wherein the step of tranεforming cellε further compriεeε uεing a recombinant vector which compriεeε εaid cDNA εequence operably linked to regulatory control εequenceε which are capable of effecting the expreεεion of said coding sequence in said transformed cell. 32. A method of modulating the production of an gastrointestinal defensin peptide in a cell comprising contacting the cell with an effective amount of a εubstance which bindε to the gene coding for the gaεtrointeεtinal defenεin peptide. 33. The method of claim 32 wherein the εtep of contacting the cell further comprises contacting the cell with a subεtance which bindε to at leaεt a portion of the nucleic acid sequence defined in SEQ ID N0:1. 34. The method of claim 33 wherein the subεtance bindε to a ciε- acting control element of SEQ ID N0:1. 35. The method of claim 33 wherein the εtep of contacting the cell further comprises contacting the cell with a subεtance which binds to at least a portion of the nucleic acid sequence defined in SEQ ID NO:4. 36. The method of claim 32 wherein the step of contacting the cell further compriseε contacting the cell with a subεtance which bindε to at leaεt a portion of the nucleic acid sequence defined in SEQ ID NO: 6. 37. A method of diagnoεing microbial infection of the gastrointestinal tract comprising detecting the amount of gastrointestinal defensin peptide preεent in a sample taken from a mammalian gaεtrointeεtinal tract and comparing the amount of peptide present in said sample with the amount of peptide preεent in a normal mammalian gaεtrointeεtinal tract, whereby an abnormal amount of εaid peptide iε indicative of the likelihood of infection. 38. The method of claim 37 wherein detecting an increaεed amount of gastrointestinal defensin peptide is indicative of infection. 39. The method of claim 37 wherein detecting a decreased amount of gastrointestinal defensin peptide is indicative of infection. 40. A method of diagnoεing gaεtrointeεtinal inflammation compriεing detecting the amount of gastrointestinal defensin peptide present in a sample taken from a mammalian gastrointestinal tract and comparing the amount of peptide present in said sample with the amount of peptide present in a normal mammalian gastrointestinal tract, whereby an abnormal amount of said peptide iε indicative of the likelihood of inflammation. 41. The method of claim 40 wherein detecting an increaεed amount of gaεtrointeεtinal defenεin peptide iε indicative of inflammation. 42. The method of claim 40 wherein detecting a decreased amount of gastrointestinal defensin peptide is indicative of inflammation. 43. A method of diagnosing microbial infection of the gastrointestinal tract comprising detecting the amount of mRNA coding for gastrointestinal defensin peptides present in a sample taken from a mammalian gastrointeεtinal tract *, nd comparing the amount of said mRNA present in said sample \_ h the amount of said mRNA present in a normal mammalian gastrointestinal tract, whereby an abnormal amount of said mRNA iε indica: xve of the likelihood of infection. 44. The method of claim 43 wherein detecting an increaεed amount of mRNA coding for gaεtrointestinal defensin peptides is indicative of infection. 45. The method of claim 43 wherein detecting a decreaεed amount of mRNA coding for gaεtrointestinal defensin peptides is indicative of infection. 46. A method of diagnosing gastrointeεtinal inflammation comprising detecting the amount of mRNA coding for gastrointeεtinal defensin peptides present in a sample taken from a mammalian gastrointeεtinal tract and comparing the amount of said mRNA present in said εample with the amount of said mRNA preεent in a normal mammalian gastrointeεtinal tract, whereby an abnormal amount of said mRNA is indicative of the likelihood of inflammation. 47. The method of claim 46 wherein detecting an increased amount of mRNA coding for gastrointeεtinal defenεin peptideε iε indicative of inflammation. 48. The method of claim 46 wherein detecting a decreaεed amount of mRNA coding for gastrointestinal defensin peptides is indicative of inflammation. 49. A method of diagnosing the susceptibility of a patient to gastrointestinal disorderε compriεing the εtepε of: providing a DNA containing teεt sample from said human patient; amplifying DNA from said DNA containing test εample using an upstream probe having a εequence complementary to an upεtream portion of a defensin sequence selected from the group consiεting of SEQ ID NO: 1, SEQ ID NO: 4 and SEQ ID NO:5 and a downεtream probe having a sequence complementary to a downstream portion of the selected defensin sequence; and comparing said amplified DNA with DNA from a normal sample to identify one or more mutations of the amplified DNA as compared to the normal DNA whereby a mutation in the amplified DNA iε indicative of the likelihood said patient haε increased susceptibility to gastrointestinal disorderε. 50. The method of claim 49 whereby the upεtream probe haε a εequence aε defined in SEQ ID NO: 48 and the downεtream probe haε a sequence as defined in SEQ ID NO: 39. 51. A method of identifying a defensin peptide comprising the steps of: screening a library of genomic clones using an oligonucleotide probe derived from evolutionarily conserved defensin sequences wherein hybridization of the probe to the clone indicates the likelihood that the clone contains a DNA sequence coding for a defensin peptide; and characterizing the clone to determine the DNA εequence encoding the defensin peptide. 52. The method of claim 51 wherein the probe comprises at least a portion of the sequence defined in SEQ ID NO:35.

Inventors: BEVINS CHARLES L, JONES DOUGLAS E, BEVINS, CHARLES, L., JONES, DOUGLAS, E.
Applicants: PHILADELPHIA CHILDREN HOSPITAL, THE CHILDREN'S HOSPITAL OF PHILADELPHIA
Application year: 1993
Main classification: C07H21
IPC codes: A61K38, A61P29, A61P31, C07K14, C12N5, C12N15, C12P19, C12P21, C12Q1, G01N33